Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction

ABSTRACT

The present invention relates to the use of compounds of formula (I) 
                         
for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein A, L, D and B 1 , are as described in the specification.

This application is a divisional of U.S. application Ser. No. 10/443,814filed on May 23, 2003, now U.S. Pat. No. 7,057,042, which claims benefitto U.S. Provisional Application Ser. No. 60/384,291, filed May 29, 2002,incorporated herein by reference.

TECHNICAL FIELD

The present invention relates to the use of fused bicyclic aromaticcompounds and compositions containing these compounds for the treatmentof sexual dysfunction.

BACKGROUND OF THE INVENTION

Preclinical evidence indicates that dopamine (DA) plays a role in penileerection in mammals. Sexual stimulation can be initiated by sensory(erotic) information reaching the cerebral cortex in mammals. Thecerebral cortex has extensive neuronal connections with limbicstructures like the amygdala, as well as midbrain structures like theperiaqueductal gray (PAG) and the hypothalamus. Two important nuclei inthe hypothalamus are the medial preoptic area (MPOA) and theparaventricular nucleus (PVN). The MPOA and PVN nuclei play a criticalrole in sexual behavior as bilateral lesions of these areas completelyeliminate male sexual behavior. The incerto-hypothalamic dopaminergicpathway that innervates the PVN and the MPOA nuclei has been associatedwith the pro-erectile effect of DA agents. Systemic administration of DAreceptor agonists like apomorphine((6aR)5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol),quinpirole and (−)3-(3-hydroxyphenyl)-N-propylpiperidine (3-PPP)facilitate penile erection in rats, an effect blocked by haloperidol, acentral DA antagonist. As the erectogenic effect can not be blocked bydomperidone, a peripheral DA antagonist, it is believed that thepro-erectile effect of DA agonists is centrally mediated.

Clinical data also indicates that DA systems in the CNS play a role onthe regulation of male sexual behavior as indicated by the sexualstimulatory effect of L-dopa in Parkinson's patients and by thepro-erectile effect of apomorphine in humans.

DA receptors belong to a superfamily of protein receptors that signalacross the cell membrane by coupling to intracellular GTP-bindingproteins. Several G proteins have been identified (including Gs, Gq andGi) that lead to specific intracellular events.

There are five known DA receptors which are classified into two groups,D₁-like and D₂-like. The D₁-like receptors include D₁ and D₅. TheD₂-like receptors include D₂, D₃ and D₄. The D₁-like family receptorsubtypes are G_(s)-coupled and can activate adenylate cyclase. TheD₂-like family receptor subtypes are G_(i)-coupled and they increaseintracellular calcium level and inhibit adenylate cyclase.

The D₁-like family members are G_(s)-coupled receptors that can activateadenylate cyclase. The D₁ receptor is the most abundant and widespreadDA receptor in the CNS both by mRNA expression and byimmunohistochemical studies. It is found in the striatum, nucleusaccumbens and olfactory tubercle as well as the limbic system,hypothalamus and thalamus. The D₁ receptor expression has been reportedin the heart and kidney, and despite that the function of theseperipheral D₁ receptors remains to be clarified, its role on the controlof hemodynamic variables has been confirmed. The D₅ receptor, whilehaving a higher affinity for DA than the D₁ receptor, is sparselydistributed in the CNS with no evidence of expression outside the CNS.

The D₂-like family members are G_(i) coupled receptors that inhibitadenylate cyclase and increase intracellular calcium levels. The D₂receptor is the most abundant of the D₂-like receptors and is located inbrain areas such as the striatum and substantia nigra, and in peripheralareas such as the heart, pituitary gland and kidney. The D₃ receptor isfound abundantly in the islands of Calleja with distinct clusterpopulations in the ventral striatum/nucleus accumbens regions, olfactorytubercle, dendate gyrus and striatal cortex.

Expression of the D₄ receptor has been documented by in situ RNAhybridization and immunohistochemical studies. Recently, studiesrevealed that D₄ expression is highest in the entorhinal cortex, lateralseptal nucleus, hippocampus and the medial preoptic area of thehypothalamus. Localization of D₄ is distinct from the distribution of D₂in the brain, as D₂ receptors are most abundant in striatal areas. Theexpression of D₄ receptors in the MPOA of the hypothalamus is ofimportance to the facilitation of penile erection in view of the role ofthe hypothalamus as an area of integration between the cortex and thespinal pathways. The participation of D₄ receptors in other CNS regions,thalamic, subthalamic and spinal can not be excluded.

The present invention identifies a therapeutic use for the compounds offormula (I) in the treatment of sexual dysfunction in mammals. Morespecifically, these compounds are useful in the treatment of sexualdysfunction including, but not limited to, male erectile dysftunction(MED).

SUMMARY OF THE INVENTION

The present invention relates to a method of treating sexual dysfunctionin a mammal, in particular humans, comprising administering to themammal a therapeutically effective amount of a compound of formula (I)

or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

A is selected from the group consisting

X is selected from CR_(X) or N;

Y is selected from NR_(Y), O, or S;

V is selected from CR_(V) or N;

P is selected from CR_(P) or N;

Q is selected from CR_(Q) or N;

S is selected from CR_(S) or N;

T is selected from CR_(T) or N;

provided that 0, 1, or 2 of P, Q, S, or T are N;

provided that when P is CR_(P), Q is CR_(Q), S is CR_(S), T is CR_(T),and Y is N, then X is CR_(X);

R_(P), R_(Q), R_(S), R_(T), R_(V), and R_(X) are independently selectedfrom hydrogen, alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl,alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy,carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy,hydroxyalkyl, mercapto, nitro, —NZ₁Z₂, (NZ₃Z₄)carbonyl, or(NZ₃Z₄)sulfonyl;

R_(Y) is selected from hydrogen, alkenyl, alkoxycarbonyl, alkyl,arylalkyl, of (NZ₃Z₄)carbonyl;

Z₁ and Z₂ are each independently selected from hydrogen, alkyl,alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl,arylsulfonyl, or formyl;

Z₃ and Z₄ are each independently selected from hydrogen, alkyl, aryl, orarylalkyl;

L is alkylene;

D is selected from

wherein the left end is attached to L and the right end is attached toB₁;

R_(A) is selected from hydrogen or alkyl;

Z is selected from N, C or CH;

--- is a bond when Z is C and --- is absent when Z is N or CH;

B₁ is selected from

R₁, R₂, R₃, R₄ and R₅ are each independently selected from hydrogen,alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio,alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy,cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl,mercapto, nitro, —NZ₁Z₂, (NZ₃Z₄)carbonyl, or (NZ₃Z₄)sulfonyl;

X₁ is selected from N(R₆), O or S;

Y₁ is selected from C(R₇) or N;

R₆ is selected from hydrogen or alkyl;

R₇ is selected from hydrogen or alkyl; and

provided that the compound of formula (I) is other than5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole.

DETAILED DESCRIPTION OF THE INVENTION

All patents, patent applications, and literature references cited in thespecification are herein incorporated by reference in their entirety.

In its principle embodiment, the present invention relates to a methodof treating sexual dysfunction in a mammal, in particular humans,comprising administering to the mammal a therapeutically effectiveamount of a compound of formula (I)

In its principle embodiment, the present invention relates to a methodof treating sexual dysfunction in a mammal, in particular humans,comprising administering to the mammal a therapeutically effectiveamount of a compound of formula (I)

or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

A is selected from the group consisting

X is selected from CR_(X) or N;

Y is selected from NR_(Y), O, or S;

V is selected from CR_(V) or N;

P is selected from CR_(P) or N;

Q is selected from CR_(Q) or N;

S is selected from CR_(S) or N;

T is selected from CR_(T) or N;

provided that 0, 1, or 2 of P, Q, S, or T are N;

provided that when P is CR_(P), Q is CR_(Q), S is CR_(S), T is CR_(T),and Y is N, then X is CR_(X);

R_(P), R_(Q), R_(S), R_(T), R_(V), and R_(X) are independently selectedfrom hydrogen, alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl,alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy,carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy,hydroxyalkyl, mercapto, nitro, —NZ₁Z₂, (NZ₃Z₄)carbonyl, or(NZ₃Z₄)sulfonyl;

R_(Y) is selected from hydrogen, alkenyl, alkoxycarbonyl, alkyl,arylalkyl, of (NZ₃Z₄)carbonyl;

Z₁ and Z₂ are each independently selected from hydrogen, alkyl,alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl,arylsulfonyl, or formyl;

Z₃ and Z₄ are each independently selected from hydrogen, alkyl, aryl, orarylalkyl;

L is alkylene;

D is selected from

wherein the left end is attached to L and the right end is attached toB₁;

R_(A) is selected from hydrogen or alkyl;

Z is selected from N, C or CH;

--- is a bond when Z is C and --- is absent when Z is N or CH;

B₁ is selected from

R₁, R₂, R₃, R₄ and R₅ are each independently selected from hydrogen,alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio,alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy,cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl,mercapto, nitro, —NZ₁Z₂, (NZ₃Z₄)carbonyl, or (NZ₃Z₄)sulfonyl;

X₁ is selected from N(R₆), O or S;

Y₁ is selected from C(R₇) or N;

R₆ is selected from hydrogen or alkyl;

R₇ is selected from hydrogen or alkyl and

provided that the compound of formula (I) is other than5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole.

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

and P, Q, S, T, X, Y, Z, R₁, R₂, R₃, R₄, R_(A), and --- are as definedin formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(T), R_(X), Z,R₁, R₂, R₃, R₄, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I),or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(P),R_(Q), R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₁,R₂, R₃, and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(P),RQ, R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is CH; --- is absent; R₁,R₂, R₃, and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(P),R_(Q), R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is C; --- is a bond; andR₁, R₂, R₃, and R₄ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, or halogen; and R_(A) is as defined in formula(I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(X), Z, R₁,R₂, R₃, R₄, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); R_(P),R_(Q), R_(S), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₁,R₂, R₃, and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); R_(P),R_(Q), R_(S), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is CH; --- is absent; R₁,R₂, R₃, and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); R_(P),R_(Q), R_(S), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is C; --- is a bond; R₁,R₂, R₃, and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(Q), R_(S), R_(T), R_(X), Z, R₁,R₂, R₃, R₄, R_(A)R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(Q), R_(S),R_(T), and R_(X) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, or S; R_(Y)is selected from hydrogen or alkyl; Z is N; --- is absent; R₁, R₂, R₃,and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(Q), R_(S),R_(T), and R_(X) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, or S; R_(Y)is selected from hydrogen or alkyl; Z is CH; --- is absent; R₁, R₂, R₃,and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I),

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(Q),R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is C; --- is a bond; R₁,R₂, R₃, and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom NR_(Y), O, or S; and R_(Q), R_(S), R_(T), Z, R₁, R₂, R₃, R₄,R_(A)R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(Q),R_(S), and R_(T) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Z is N; --- is absent; R₁, R₂, R₃, and R₄are independently selected from hydrogen, alkoxy, alkyl, alkylthio,cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(Q),R_(S), and R_(T) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Z is CH; --- is absent; R₁, R₂, R₃, and R₄are independently selected from hydrogen, alkoxy, alkyl, alkylthio,cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(Q),R_(S), and R_(T) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Z is C; --- is a bond; R₁, R₂, R₃, and R₄are independently selected from hydrogen, alkoxy, alkyl, alkylthio,cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; and R_(P), R_(Q), R_(S), Z, R₁, R₂, R₃, R₄, R_(A),R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(P),R_(Q), and R_(S) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Z is N; --- is absent; R₁, R₂, R₃, and R₄are independently selected from hydrogen, alkoxy, alkyl, alkylthio,cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(P),R_(Q), and R_(S) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Z is CH; --- is absent; R₁, R₂, R₃, and R₄are independently selected from hydrogen, alkoxy, alkyl, alkylthio,cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(P),R_(Q), and R_(S) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Z is C; --- is a bond; R₁, R₂, R₃, and R₄are independently selected from hydrogen, alkoxy, alkyl, alkylthio,cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

and P, Q, S, T, X, Y, R₁, R₂, R₃, R₄, and R_(A) are as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(T), R_(X),R₁, R₂, R₃, R₄, R_(Y), and R_(A) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(P),R_(Q), R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; R₁, R₂, R₃, and R₄ areindependently selected from hydrogen, alkoxy, alkyl, alkylthio, cyano,or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(X), R₁, R₂,R₃, R₄, R_(Y), and R_(A) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); R_(P),R_(Q), R_(S), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; R₁, R₂, R₃, and R₄ areindependently selected from hydrogen, alkoxy, alkyl, alkylthio, cyano,or halogen; and R_(A) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(Q), R_(S), R_(T), R_(X), R₁, R₂,R₃, R₄, R_(Y), and R_(A) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(Q),R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; R₁, R₂, R₃, and R₄ areindependently selected from hydrogen, alkoxy, alkyl, alkylthio, cyano,or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom NR_(Y), O, or S; and R_(Q), R_(S), R_(T), R₁, R₂, R₃, R₄, R_(Y),and R_(A) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(Q),R_(S), and R_(T) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; R₁, R₂, R₃, and R₄ are independentlyselected from hydrogen, alkoxy, alkyl, alkylthio, cyano, or halogen; andR_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R₁, R₂, R₃, R₄, R_(Y),and R_(A) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(P),R_(Q), and R_(S) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; R₁, R₂, R₃, and R₄ are independentlyselected from hydrogen, alkoxy, alkyl, alkylthio, cyano, or halogen; andR_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

and P, Q, S, T, X, Y, R₁, R₂, R₃, R₄, and R_(A) are as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(T), R_(X),R₁, R₂, R₃, R₄, R_(Y), and R_(A) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, oxide, orprodrug thereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(P),R_(Q), R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; R₁, R₂, R₃, and R₄ areindependently selected from hydrogen, alkoxy, alkyl, alkylthio, cyano,or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(X), R₁, R₂,R₃, R₄, R_(Y), and R_(A) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); R_(P),R_(Q), R_(S), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; R₁, R₂, R₃, and R₄ areindependently selected from hydrogen, alkoxy, alkyl, alkylthio, cyano,or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(Q), R_(S), R_(T), R_(X), R₁, R₂,R₃, R₄, R_(Y), and R_(A) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(Q),R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; R₁, R₂, R₃, and R₄ areindependently selected from hydrogen, alkoxy, alkyl, alkylthio, cyano,or halogen; and R_(A) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom NR_(Y), O, or S; and R_(Q), R_(S), R_(T), R₁, R₂, R₃, R₄, R_(Y),and R_(A) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual 5 dysfunction in a mammal comprising administering tothe mammal a therapeutically effective amount of a compound of formula(I) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(Q),R_(S), and R_(T) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; R₁, R₂, R₃, and R₄ are independentlyselected from hydrogen, alkoxy, alkyl, alkylthio, cyano, or halogen; andR_(A) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R₁, R₂, R₃, R₄, R_(Y),and R_(A) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(P),R_(Q), and R_(S) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; R₁, R₂, R₃, and R₄ are independentlyselected from hydrogen, alkoxy, alkyl, alkylthio, cyano, or halogen; andR_(A) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

and P, Q, S, T, X, Y, Z, R₁, R₂, R₃, R₄, R₅, R_(A), and --- are asdefined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(T), R_(X), Z,R₁, R₂, R₃, R₄, R₅, R_(A)R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(P),R_(Q), R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₁,R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(P),R_(Q), R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is CH; --- is absent; R₁,R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(P),R_(Q), R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is C; --- is a bond; R₁,R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(X), Z, R₁,R₂, R₃, R₄, R₅, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); R_(P),R_(Q), R_(S), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₁,R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof,

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); R_(P),R_(Q), R_(S), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is CH; --- is absent; R₁,R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); R_(P),R_(Q), R_(S), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is C; --- is a bond; R₁,R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(Q), R_(S), R_(T), R_(X), Z, R₁,R₂, R₃, R₄, R₅, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(Q),R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; andR₁, R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(Q),R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is CH; ---- is absent;R₁, R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(Q),R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is C; --- is a bond; R₁,R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom NR_(Y), O, or S; and R_(Q), R_(S), R_(T), Z, R₁, R₂, R₃, R₄, R₅,R_(A)R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; R_(Q), R_(S), andR_(T) are independently selected from hydrogen, alkoxy, alkyl,haloalkyl, or halogen; Y is selected from NR_(Y), O, or S; R_(Y) isselected from hydrogen or alkyl; Z is N; --- is absent; R₁, R₂, R₃, R₄,and R₅ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; R_(Q), R_(S), andR_(T) are independently selected from hydrogen, alkoxy, alkyl,haloalkyl, or halogen; Y is selected from NR_(Y), O, or S; R_(Y) isselected from hydrogen or alkyl; Z is CH; --- is absent; R₁, R₂, R₃, R₄,and R₅ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; R_(Q), R_(S), andR_(T) are independently selected from hydrogen, alkoxy, alkyl,haloalkyl, or halogen; Y is selected from NR_(Y), O, or S; R_(Y) isselected from hydrogen or alkyl; Z is C; --- is a bond; R₁, R₂, R₃, R₄,and R₅ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; and R_(P), R_(Q), R_(S), Z, R₁, R₂, R₃, R₄, R₅,R_(A)R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(P),R_(Q), and R₅ are independently selected from hydrogen, alkoxy, alkyl,haloalkyl, or halogen; Z is N; --- is absent; R₁, R₂, R₃, R₄, and R₅ areindependently selected from hydrogen, alkoxy, alkyl, alkylthio, cyano,halogen, or hydroxy; and RA is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, oxide, orprodrug thereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(P),R_(Q), and R_(S) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Z is CH; --- is absent; R₁, R₂, R₃, R₄,and R₅ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(P),R_(Q), and R_(S) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Z is C; --- is a bond; R₁, R₂, R₃, R₄, andR₅ are independently selected from hydrogen, alkoxy, alkyl, alkylthio,cyano, halogen, or hydroxy; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

and P, Q, S, T, X, Y, R₁, R₂, R₃, R₄, R₅, and R_(A) are as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(T), R_(X),R₁, R₂, R₃, R₄, R₅, R_(A)and R_(Y) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(P),R_(Q), R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; R₁, R₂, R₃, R₄, and R₅ areindependently selected from hydrogen, alkoxy, alkyl, alkylthio, cyano,halogen, or hydroxy; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(X), R₁, R₂,R₃, R₄, R₅, R_(A), and R_(Y) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); R_(P),R_(Q), R_(S), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; R₁, R₂, R₃, R₄, and R₅ areindependently selected from hydrogen, alkoxy, alkyl, alkylthio, cyano,halogen, or hydroxy; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(Q), R_(S), R_(T), R_(X), R₁, R₂,R₃, R₄, R₅, R_(A), and R_(Y) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(Q),R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; R₁, R₂, R₃, R₄, and R₅ areindependently selected from hydrogen, alkoxy, alkyl, alkylthio, cyano,halogen, or hydroxy; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom NR_(Y), O, or S; and R_(Q), R_(S), R_(T), R₁, R₂, R₃, R₄, R₅,R_(A), and R_(Y) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(Q),R_(S), and R_(T) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; R₁, R₂, R₃, R₄, and R₅ are independentlyselected from hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, orhydroxy; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R₁, R₂, R₃, R₄, R₅,R_(A), and R_(Y) are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(P),R_(Q), and R_(S) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; R₁, R₂, R₃, R₄, and R₅ are independentlyselected from hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, orhydroxy; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

and P, Q, S, T, X, Y, Z, R₂, R₃, R₄, R_(A)and --- are as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(T), R_(X), Z,R₂, R₃, R₄, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(P),R_(Q), R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₂,R₃, and R₄ are independently selected from hydrogen, alkyl, or halogen;and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(X), Z, R₂,R₃, R₄, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); R_(P),R_(Q), R_(S), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₂,R₃, and R₄ are independently selected from hydrogen, alkyl, or halogen;and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(Q), R_(S), R_(T), R_(X), Z, R₂,R₃, R₄, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(Q),R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₂,R₃, and R₄ are independently selected from hydrogen, alkyl, or halogen;and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom NR_(Y), O, or S; and R_(Q), R_(S), R_(T), Z, R₂, R₃, R₄, R_(A),R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(Q),R_(S), and R_(T) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Z is N; --- is absent; R₂, R₃, and R₄ areindependently selected from hydrogen, alkyl, or halogen; and R_(A) is asdefined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; and R_(P), R_(Q), R_(S), Z, R₂, R₃, R₄, R_(A),R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(P),R_(Q), and R_(S) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Z is N; --- is absent; R₂, R₃, and R₄ areindependently selected from hydrogen, alkyl, or halogen; and R_(A) is asdefined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

and P, Q, S, T, X, Y, Z, X₁, Y₁, R₂, R₃, R_(A), and --- are as definedin formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(T), R_(X), Z,X₁, Y₁, R₂, R₃, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(P),R_(Q), R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; X₁ is S; Y₁ is N; Z is N;--- is absent; R₂ and R₃ are independently selected from hydrogen,alkyl, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(X), Z, X₁,Y₁, R₂, R₃, R_(A), R_(Y), and -- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is CR_(X); R_(P),R_(Q), R_(S), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; X₁ is S; Y₁ is N; R_(Y) is selected from hydrogen or alkyl; Z is N;--- is absent; R₂ and R₃ are independently selected from hydrogen,alkyl, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from NR_(Y), O, or S; and R_(Q), R_(S), R_(T), R_(X), Z, X₁,Y₂, R₂, R₃, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); R_(Q),R_(S), R_(T), and R_(X) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; X₁ is S; Y₁ is N; Z is N;--- is absent; R₂ and R₃ are independently selected from hydrogen,alkyl, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(a); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom NR_(Y), O, or S; and R_(Q), R_(S), R_(T), Z, X₁, Y₁, R₂, R₃, R_(A),R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(Q),R_(S), and R_(T) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; X₁ is S; Y₁ is N; Z is N; --- is absent;R₂ and R₃ are independently selected from hydrogen, alkyl, or halogen;and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; and R_(P), R_(Q), R_(S), Z, X₁, Y₁, R₂, R₃, R_(A),R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom NR_(Y), O, or S; R_(Y) is selected from hydrogen or alkyl; R_(P),R_(Q), and R_(S) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; X₁ is S; Y₁ is N; Z is N; --- is absent;R₂ and R₃ are independently selected from hydrogen, alkyl, or halogen;and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

and P, Q, S, T, V, Y, Z, R₁, R₂, R₃, R₄, R_(A), and --- are as definedin formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(T), R_(V), Z,R₁, R₂, R₃, R₄, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); R_(P),R_(Q), R_(S), R_(T), and R_(V) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₁,R₂, R₃, and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); R_(P),R_(Q), R_(S), R_(T), and R_(V) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is CH; --- is absent; R₁,R₂, R₃, and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); R_(P),R_(Q), R_(S), R_(T), and R_(V) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is C; --- is a bond; R₁,R₂, R₃, and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; V is CR_(V); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(V), Z, R₁,R₂, R₃, R₄, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; V is CR_(V); R_(P),R_(Q), R_(S), and R_(V) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₁,R₂, R₃, and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; V is CR_(V); R_(P),R_(Q), R_(S), and R_(V) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is CH; --- is absent; R₁,R₂, R₃, and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; V is CR_(V); R_(P),R_(Q), R_(S), and R_(V) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is C; --- is a bond; R₁,R₂, R₃, and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); Y isselected from NR_(Y), O, or S; and R_(Q), R_(S), R_(T), R_(V), Z, R₁,R₂, R₃, R₄, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); R_(Q),R_(S), R_(T) and R_(V) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, or S; R_(Y)is selected from hydrogen or alkyl; Z is N; --- is absent; R₁, R₂, R₃,and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); R_(Q),R_(S), R_(T) and R_(V) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, or S; R_(Y)is selected from hydrogen or alkyl; Z is CH; --- is absent; R₁, R₂, R₃,and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); R_(Q),R_(S), R_(T) and R_(V) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, or S; R_(Y)is selected from hydrogen or alkyl; Z is C; --- is a bond; R₁, R₂, R₃,and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P, Q, S, T, V, Y, Z, R₁, R₂, R₃, R₄, R₅, R_(A), and --- are as definedin formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(T), R_(V), Z,R₁, R₂, R₃, R₄, R₅, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); R_(P),R_(Q), R_(S), R_(T), and R_(V) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₁,R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); R_(P),R_(Q), R_(S), R_(T), and R_(V) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is CH; --- is absent; R₁,R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); R_(P),R_(Q), R_(S), R_(T), and R_(V) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is C; --- is a bond; R₁,R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; V is CR_(V); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(V), Z, R₁,R₂, R₃, R₄, R₅, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; V is CR_(V); R_(P),R_(Q), R_(S), and R_(V) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₁,R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, oxide, orprodrug thereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; V is CR_(V); R_(P),R_(Q), and R_(V) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, or S; R_(Y)is selected from hydrogen or alkyl; Z is CH; --- is absent; R₁, R₂, R₃,R₄, and R₅ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; V is CR_(V); R_(P),R_(Q), R_(S), and R_(V) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is C; --- is a bond; R₁,R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); Y isselected from NR_(Y), O, or S; and R_(Q), R_(S), R_(T), R_(V), Z, R₁,R₂, R₃, R₄, R₅, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); R_(Q),R_(S), R_(T) and R_(V) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, or S; R_(Y)is selected from hydrogen or alkyl; Z is N; --- is absent; R₁, R₂, R₃,R₄, and R₅ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); R_(Q),R_(S), R_(T) and R_(V) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, or S; R_(Y)is selected from hydrogen or alkyl; Z is CH; --- is absent; R₁, R₂, R₃,R₄, and R₅ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, halogen, or hydroxy; and RA is as defined in formula(I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); R_(Q),R_(S), R_(T) and R_(V) are independently selected from hydrogen, alkoxy,alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, or S; R_(Y)is selected from hydrogen or alkyl; Z is C; --- is a bond; R₁, R₂, R₃,R₄, and R₅ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, halogen, or hydroxy; and RA is as defined in formula(I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

and P, Q, S, T, V, Y, Z, R₂, R₃, R₄, R_(A), and --- are as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), R_(S), R_(T), R_(V), Z,R₂, R₃, R₄, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); R_(P),R_(Q), R_(S), R_(T), and R_(V) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₂,R₃, and R₄ are independently selected from hydrogen, alkyl, or halogen;and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; V is CR_(V); Y isselected from NR_(Y), O, or S; and R_(P), R_(Q), P_(S), R_(V), Z, R₂,R₃, R₄, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; V is CR_(V); R_(P),R_(Q), R_(S), and R_(V) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₂,R₃, and R₄ are independently selected from hydrogen, alkyl, or halogen;and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); Y isselected from NR_(Y), O, or S; and R_(Q), R_(S), R_(T), R_(V), Z, R₂,R₃, R₄, R_(A), R_(Y), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); V is CR_(V); R_(Q),R_(S), R_(T), and R_(V) are independently selected from hydrogen,alkoxy, alkyl, haloalkyl, or halogen; Y is selected from NR_(Y), O, orS; R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₂,R₃, and R₄ are independently selected from hydrogen, alkyl, or halogen;and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

and Z, R₁, R₂, R₃, R₄, R_(Y), R_(A), and --- are as defined in formula(I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₁, R₂,R₃, and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

and Z, R₁, R₂, R₃, R₄, R₅, R_(Y), R_(A), and --- are as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₁, R₂,R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

Z, R₂, R₃, R₄, R_(Y), R_(A), and --- are as defined in formula (I).

In another embodiment, the present invention relates to a method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, wherein

is selected from hydrogen or alkyl; Z is N; --- is absent; R₂, R₃, andR₄ are independently selected from hydrogen, alkyl, or halogen; andR_(A) is as defined in formula (I).

In another embodiment, the present invention relates to method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof in combination with a pharmaceutically acceptable carrier.

In another embodiment, the present invention relates to method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof in combination with a phosphodiesterase 5 inhibitor.

In another embodiment, the present invention relates to method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof in combination with an adrenergic receptor antagonist.

In another embodiment, the present invention relates to method oftreating sexual dysfunction in a mammal comprising administering to themammal a therapeutically effective amount of a compound of formula (I)or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof in combination with a dopamine agonist.

In another embodiment, the present invention relates to method oftreating male erectile dysfunction in a male human comprisingadministering to the male human in need of such treatment atherapeutically effective amount of a compound of formula (I) or apharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof in combination with a pharmaceutically acceptable carrier.

In another embodiment, the present invention relates to method oftreating male erectile dysfunction in a mammal comprising administeringto the mammal a therapeutically effective amount of a compound offormula (I) or a pharmaceutically acceptable salt, ester, amide,N-oxide, or prodrug thereof in combination with a phosphodiesterase 5inhibitor.

In another embodiment, the present invention relates to method oftreating male erectile dysfunction in a mammal comprising administeringto the mammal a therapeutically effective amount of a compound offormula (I) or a pharmaceutically acceptable salt, ester, amide,N-oxide, or prodrug thereof in combination with an adrenergic receptorantagonist.

In another embodiment, the present invention relates to method oftreating male erectile dysfunction in a mammal comprising administeringto the mammal a therapeutically effective amount of a compound offormula (I) or a pharmaceutically acceptable salt, ester, amide,N-oxide, or prodrug thereof in combination with a dopamine agonist.

In another embodiment, the present invention relates to method oftreating female sexual dysfunction in a mammal comprising administeringto the mammal in need of such treatment a therapeutically effectiveamount of a compound of formula (I) or a pharmaceutically acceptablesalt, ester, amide, N-oxide, or prodrug thereof in combination with apharmaceutically acceptable carrier.

In another embodiment, the present invention relates to method oftreating female sexual dysfunction in a mammal comprising administeringto the mammal a therapeutically effective amount of a compound offormula (I) or a pharmaceutically acceptable salt, ester, amide,N-oxide, or prodrug thereof in combination with a phosphodiesterase 5inhibitor.

In another embodiment, the present invention relates to method oftreating female sexual dysfunction in a mammal comprising administeringto the mammal a therapeutically effective amount of a compound offormula (I) or a pharmaceutically acceptable salt, ester, amide,N-oxide, or prodrug thereof in combination with an adrenergic receptorantagonist.

In another embodiment, the present invention relates to method oftreating female sexual dysfunction in a mammal comprising administeringto the mammal a therapeutically effective amount of a compound offormula (I) or a pharmaceutically acceptable salt, ester, amide,N-oxide, oxide, or prodrug thereof in combination with a dopamineagonist.

In another embodiment, the present invention relates to method oftreating a disorder selected from cardiovascular disorders, inflammatorydisorders, attention deficit hyperactivity disorder, Alzheimer'sdisease, drug abuse, Parkinson's disease, schizophrenia, anxiety, mooddisorders or depression in a mammal comprising administering to themammal in need of such treatment a therapeutically effective amount of acompound of formula (I) or a pharmaceutically acceptable salt, ester,amide, N-oxide, or prodrug thereof

In another embodiment of the present invention, compounds of formula(II)

or a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof, are disclosed wherein

A is selected from the group consisting

X is selected from CR_(X) or N;

Y is selected from O, or S;

V is selected from CR_(V) or N;

P is selected from CR_(P) or N;

Q is selected from CR_(Q) or N;

S is selected from CR_(S) or N;

T is selected from CR_(T) or N;

provided that 1, or 2 of P, Q, S, and T are N;

R_(P), R_(Q), R_(S), R_(T), R_(V), and R_(X) are independently selectedfrom hydrogen, alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl,alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy,carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy,hydroxyalkyl, mercapto, nitro, —NZ₁Z₂, (NZ₃Z₄)carbonyl, or(NZ₃Z₄)sulfonyl;

Z₁ and Z₂ are each independently selected from hydrogen, alkyl,alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl,arylsulfonyl, or formyl;

Z₃ and Z₄ are each independently selected from hydrogen, alkyl, aryl, orarylalkyl;

L is alkylene;

D is selected from

wherein the left end is attached to L and the right end is attached toB₁;

R_(A) is selected from hydrogen or alkyl;

Z is selected from N, C or CH;

--- is a bond when Z is C and --- is absent when Z is N or CH;

B₁ is selected from

R₁, R₂, R₃, R₄ and R₅ are each independently selected from hydrogen,alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio,alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy,cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl,mercapto, nitro, —NZ₁Z₂, (NZ₃Z₄)carbonyl, or (NZ₃Z₄)sulfonyl;

X₁ is selected from N(R₆), O or S;

Y₁ is selected from C(R₇) or N;

R₆ is selected from hydrogen or alkyl; and

R₇ is selected from hydrogen or alkyl.

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein A is

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from O or S; and R_(Q), R_(S), R_(T), and R_(X) are as definedin formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from O or S; and Z, R_(Q), R_(S), R_(T), R_(X), R₁, R₂, R₃, R₄,R_(A) and --- are as defined in formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein A is

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from O or S; R_(Q), R_(S), R_(T), and R_(X) are independentlyselected from hydrogen, alkoxy, alkyl, haloalkyl, or halogen; Z is N;--- is absent; R₁, R₂, R₃, and R₄ are independently selected fromhydrogen, alkoxy, alkyl, alkylthio, cyano, or halogen; and R_(A) is asdefined in formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from O or S; and R_(Q), R_(S), R_(T), and Z, R_(Q), R_(S),R_(T), R_(X), R₁, R₂, R₃, R₄, R₅, R_(A) and --- are as defined informula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is CR_(X); Y isselected from O or S; R_(Q), R_(S), R_(T), and R_(X) are independentlyselected from hydrogen, alkoxy, alkyl, haloalkyl, or halogen; Z is N;--- is absent; R₁, R₂, R₃, R₄, and R_(S) are independently selected fromhydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, or hydroxy; andR_(A) is as defined in formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom O or S; and Z, R_(Q), R_(S), R_(T), R₁, R₂, R₃, R₄, R_(A) and ---are as defined in formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom O or S; R_(Q), R_(S), and R_(T) are independently selected fromhydrogen, alkoxy, alkyl, haloalkyl, or halogen; Z is N; --- is absent;R₁, R₂, R₃, and R₄ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, or halogen; and R_(A) is as defined in formula(II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selected fromO or S; and Z, R_(Q), R_(S), R_(T), R₁, R₂, R₃, R₄, R₅, R_(A) and ---are as defined in formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

P is N; Q is CR_(Q); S is CR_(S); T is CR_(T); X is N; Y is selectedfrom O or S; R_(Q), R_(S), and R_(T) are independently selected fromhydrogen, alkoxy, alkyl, haloalkyl, or halogen; Z is N; --- is absent;R₁, R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom O or S; and Z, R_(P), R_(Q), R_(S), R₁, R₂, R₃, R₄, R_(A) and ---are as defined in formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom O or S; R_(P), R_(Q), and R_(S) are independently selected fromhydrogen, alkoxy, alkyl, haloalkyl, or halogen; Z is N; --- is absent;R₁, R₂, R₃, and R₄ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, or halogen; and R_(A) is as defined in formula(II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom O or S; R_(P), R_(Q), and R_(S) are independently selected from thegroup consisting of hydrogen, alkoxy, alkyl, haloalkyl, or halogen; Z isCH; --- is absent; R₁, R₂, R₃, and R₄ are independently selected fromthe group consisting of hydrogen, alkoxy, alkyl, alkylthio, cyano, orhalogen; and R_(A) is as defined in formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom O or S; and Z, R_(P), R_(Q), R_(S), R₁, R₂, R₃, R₄, R₅, R_(A) and--- are as defined in formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom O or S; R_(P), R_(Q), and R_(S) are independently selected fromhydrogen, alkoxy, alkyl, haloalkyl, or halogen; Z is N; --- is absent;R₁, R₂, R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom O or S; and Z, R_(P), R_(Q), R_(S), R₂, R₃, R₄, R_(A) and --- areas defined in formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom O or S; R_(P), R_(Q), and R_(S) are independently selected fromhydrogen, alkoxy, alkyl, haloalkyl, or halogen; Z is N; --- is absent;R₂, R₃, and R₄ are independently selected from hydrogen, alkyl, orhalogen; and R_(A) is as defined in formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom O or S; and X₁, Y₁, Z, R_(P), R_(Q), R_(S), R₂, R₃, R_(A) and ---are defined in formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

P is CR_(P); Q is CR_(Q); S is CR_(S); T is N; X is N; Y is selectedfrom O or S; R_(P), R_(Q), and R_(S) are independently selected fromhydrogen, alkoxy, alkyl, haloalkyl, or halogen; X₁ is S; Y₁ is N; Z isN; --- is absent; R₂, and R₃ are independently selected from hydrogen,alkyl, or halogen; and R_(A) is as defined in formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

and R_(Y) is as defined in formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₁, R₂,R₃, and R₄ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, or halogen; and R_(A) is as defined in formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

and R_(Y), R_(A), Z, R₁, R₂, R₃, R₄, R₅, and --- are as defined informula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₁, R₂,R₃, R₄, and R₅ are independently selected from hydrogen, alkoxy, alkyl,alkylthio, cyano, halogen, or hydroxy; and R_(A) is as defined informula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

and R_(Y), R_(A), Z, R₂, R₃, R₄, and --- are as defined in formula (II).

In another embodiment of the present invention, compounds of formula(II) or a pharmaceutically acceptable salt, ester, amide, N-oxide, orprodrug thereof, are disclosed wherein

R_(Y) is selected from hydrogen or alkyl; Z is N; --- is absent; R₂, R₃,and R₄ are independently selected from hydrogen, alkyl, or halogen; andR_(A) is as defined in formula (II).Definitions of the Present Invention

As used throughout this specification and the appended claims, thefollowing terms have the following meanings:

The term “alkenyl” as used herein, means a straight or branched chainhydrocarbon containing from 2 to 10 carbons and containing at least onecarbon-carbon double bond formed by the removal of two hydrogens.Representative examples of alkenyl include, but are not limited to,ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl,5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.

The term “alkoxy” as used herein, means an alkyl group, as definedherein, appended to the parent molecular moiety through an oxygen atom.Representative examples of alkoxy include, but are not limited to,methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, andhexyloxy.

The term “alkoxycarbonyl” as used herein, means an alkoxy group, asdefined herein, appended to the parent molecular moiety through acarbonyl group, as defined herein. Representative examples ofalkoxycarbonyl include, but are not limited to, methoxycarbonyl,ethoxycarbonyl, and tert-butoxycarbonyl.

The term “alkyl” as used herein, means a straight or branched chainhydrocarbon containing from 1 to 10 carbon atoms. Representativeexamples of alkyl include, but are not limited to, methyl, ethyl,n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl,n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl,2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, andn-decyl.

The term “alkylcarbonyl” as used herein, means an alkyl group, asdefined herein, appended to the parent molecular moiety through acarbonyl group, as defined herein. Representative examples ofalkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl,2,2-dimethyl-1-oxopropyl, 1-oxobutyl, and 1-oxopentyl.

The term “alkylcarbonyloxy” as used herein, means an alkylcarbonylgroup, as defined herein, appended to the parent molecular moietythrough an oxygen atom. Representative examples of alkylcarbonyloxyinclude, but are not limited to, acetyloxy, ethylcarbonyloxy, andtert-butylcarbonyloxy.

The term “alkylene” means a divalent group derived from a straight orbranched chain hydrocarbon of from 1 to 10 carbon atoms. Representativeexamples of alkylene include, but are not limited to, —CH₂—, —CH(CH₃)——CH₂CH₂—, —CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂—, and —CH₂CH(CH₃)CH₂—.

The term “alkylsulfinyl” as used herein, means an alkyl group, asdefined herein, appended to the parent molecular moiety through asulfinyl group, as defined herein. Representative examples ofalkylsulfinyl include, but are not limited to, methylsulfinyl andethylsulfinyl.

The term “alkylsulfonyl” as used herein, means an alkyl group, asdefined herein, appended to the parent molecular moiety through asulfonyl group, as defined herein. Representative examples ofalkylsulfonyl include, but are not limited to, methylsulfonyl andethylsulfonyl.

The term “alkylthio” as used herein, means an alkyl group, as definedherein, appended to the parent molecular moiety through a sulfur atom.Representative examples of alkylthio include, but are not limited,methylthio, ethylthio, tert-butylthio, and hexylthio.

The term “alkynyl” as used herein, means a straight or branched chainhydrocarbon group containing from 2 to 10 carbon atoms and containing atleast one carbon-carbon triple bond. Representative examples of alkynylinclude, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl,3-butynyl, 2-pentynyl, and 1-butynyl.

The term “aryl” as used herein, means a monocyclic-ring system, or abicyclic- or a tricyclic-fused ring system wherein one or more of thefused rings are aromatic. Representative examples of aryl include, butare not limited to, anthracenyl, azulenyl, fluorenyl,2,3-dihydroindenyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl.

The aryl groups of this invention are substituted with 0, 1, 2, 3, 4, or5 substituents independently selected from alkoxy, alkenyl, alkyl,alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl,alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen,haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, —NZ₁Z₂,(NZ₃Z₄)carbonyl, and (NZ₃Z₄)sulfonyl.

The term “arylalkyl” as used herein, means an aryl group, as definedherein, appended to the parent molecular moiety through an alkyl group,as defined herein. Representative examples of arylalkyl include, but arenot limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, and2-naphth-2-ylethyl.

The term “arylalkylsulfonyl” as used herein, means an arylalkyl group,as defined herein, appended to the parent molecular moiety through asulfonyl group.

The term “arylsulfonyl” as used herein, means an aryl group, as definedherein, appended to the parent molecular moiety through a sulfonylgroup.

The term “carbonyl” as used herein, means a —C(O)— group.

The term “carboxy” as used herein, means a —CO₂H group.

The term “cyano” as used herein, means a —CN group.

The term “formyl” as used herein, means a —C(O)H group.

The term “halo” or “halogen” as used herein, means —Cl, —Br, —I or —F.

The term “haloalkoxy” as used herein, means at least one halogen, asdefined herein, appended to the parent molecular moiety through analkoxy group, as defined herein. Representative examples of haloalkoxyinclude, but are not limited to, chloromethoxy, 2-fluoroethoxy,trifluoromethoxy, and pentafluoroethoxy.

The term “haloalkyl” as used herein, means at least one halogen, asdefined herein, appended to the parent molecular moiety through an alkylgroup, as defined herein. Representative examples of haloalkyl include,but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl,pentafluoroethyl, and 2-chloro-3-fluoropentyl.

The term “hydroxy” as used herein, means an —OH group.

The term “hydroxyalkyl” as used herein, means at least one hydroxygroup, as defined herein, appended to the parent molecular moietythrough an alkyl group, as defined herein. Representative examples ofhydroxyalkyl include, but are not limited to, hydroxymethyl,2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and2-ethyl-4-hydroxyheptyl.

The term “mercapto” as used herein, means a —SH group.

The term “nitrogen protecting group” as used herein, means those groupsintended to protect an amino group against undesirable reactions duringsynthetic procedures. Nitrogen protecting groups comprise carbamates,amides, N-benzyl derivatives, and imine derivatives. Preferred nitrogenprotecting groups are acetyl, benzoyl, benzyl, benzyloxycarbonyl (Cbz),formyl, phenylsulfonyl, pivaloyl, tert-butoxycarbonyl (Boc),tert-butylacetyl, trifluoroacetyl, and triphenylmethyl (trityl).

The term “nitro” as used herein, means a —NO₂ group.

The term “(NZ₃Z₄)carbonyl” as used herein, means a —NZ₃Z₄ group, asdefined herein, appended to the parent molecular moiety through acarbonyl group, as defined herein. Representative examples of(NZ₃Z₄)carbonyl include, but are not limited to, aminocarbonyl,(methylamino)carbonyl, (dimethylamino)carbonyl, benzylamino,phenylamino, and (ethylmethylamino)carbonyl.

The term “(NZ₃Z₄)sulfonyl” as used herein, means a —NZ₃Z₄ group, asdefined herein, appended to the parent molecular moiety through asulfonyl group, as defined herein.

The term “oxo” as used herein, means a ═O moiety.

The term “sulfinyl” as used herein, means a —S(O)— group.

The term “sulfonyl” as used herein, means a —SO₂— group.

The term “sexual dysfunction” as used herein, means sexual dysfunctionin mammals including human male and human female sexual dysfunction.

The term “male sexual dysfunction” as used herein includes, but is notlimited to, male erectile dysfunction or premature ejacualtion.

The term “female sexual dysfunction” as used herein includes, but is notlimited to, female anorgasmia, clitoral erectile insufficiency, vaginalengorgement, dyspareunia, or vaginismus.

Compounds of the present invention may exist as stereoisomers wherein,asymmetric or chiral centers are present. These stereoisomers are “R” or“S” depending on the configuration of substituents around the chiralcarbon atom. The terms “R” and “S” used herein are configurations asdefined in IUPAC 1974 Recommendations for Section E, FundamentalStereochemistry, Pure Appl. Chem., 1976, 45: 13–30. The presentinvention contemplates various stereoisomers and mixtures thereof andare specifically included within the scope of this invention.Stereoisomers include enantiomers and diastereomers, and mixtures ofenantiomers or diastereomers. Individual stereoisomers of compounds ofthe present invention may be prepared synthetically from commerciallyavailable starting materials which contain asymmetric or chiral centersor by preparation of racemic mixtures followed by resolution well-knownto those of ordinary skill in the art. These methods of resolution areexemplified by (1) attachment of a mixture of enantiomers to a chiralauxiliary, separation of the resulting mixture of diastereomers byrecrystallization or chromatography and liberation of the optically pureproduct from the auxiliary or (2) direct separation of the mixture ofoptical enantiomers on chiral chromatographic columns.

Compounds of the present invention were named by ACD/ChemSketch version5.0 (developed by Advanced Chemistry Development, Inc., Toronto, ON,Canada) or were given names which appeared to be consistent with ACDnomenclature.

Preferred compounds of the present invention include:

2-{1-[(5-chloro-1-benzothien-3-yl)methyl]-4-piperidinyl}pyridine;

1-[(5-chloro-1-benzothien-3-yl)methyl]-4-(6-methyl-2-pyridinyl)piperazine;

2-{4-[(5-chloro-1-benzothien-3-yl)methyl]-1-piperazinyl}benzonitrile;

1-[(5-chloro-1-benzothien-3-yl)methyl]-4-(2-pyridinyl)piperazine;

1-[(5-chloro-1-benzothien-3-yl)methyl]-4-(2-fluorophenyl)piperazine;

2-{4-[(5-chloro-1-benzothien-3-yl)methyl]-1-piperazinyl}pyrimidine;

1-(1-benzothien-3-ylmethyl)-4-(2-pyridinyl)piperazine;

2-[4-(1-benzothien-2-ylmethyl)-1-piperazinyl]benzonitrile;

1-(1-benzothien-2-ylmethyl)-4-(2-fluorophenyl)piperazine;

1-(1-benzothien-2-ylmethyl)-4-(2-pyridinyl)piperazine;

2-{4-[(5-fluoro-1H-indol-2-yl)methyl]-1,4-diazepan-1-yl}benzonitrile;

2-{1-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-1H-indole;

2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}-1-methyl-1H-indole;

2-{1-[4-(2-pyridinyl)-1-piperazinyl]ethyl}-1H-indole;

5-fluoro-2-{[(1S,4S)-5-(2-pyridinyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}-1H-indole;

5-fluoro-2-{[4-(2-pyridinyl)-1,4-diazepan-1-yl]methyl}-1H-indole;

2-[4-(1H-pyrrolo[2,3-b]pyridin-2-ylmethyl)-1-piperazinyl]benzonitrile;

2-{[4-(2-pyrimidinyl)-1-piperazinyl]methyl}-1H-pyrrolo[2,3-b]pyridine;

2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}-1H-pyrrolo[2,3-b]pyridine;

2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-pyrrolo[2,3-b]pyridine;

2-[(4-phenyl-1-piperazinyl)methyl]-1H-pyrrolo[2,3-b]pyridine;

2-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}-1H-pyrrolo[2,3-b]pyridine;

2-[4-(1H-pyrrolo[2,3-b]pyridin-2-ylmethyl)-1-piperazinyl]nicotinonitrile;

4-(4-{[6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]methyl}-1-piperazinyl)phenol;

2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}-6-(trifluoromethyl)thieno[3,2-b]pyridine;

2-(4-{[6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]methyl}-1-piperazinyl)benzonitrile;

4-[4-(furo[3,2-b]pyridin-2-ylmethyl)-1-piperazinyl]phenol;

2-[(4-phenyl-1-piperazinyl)methyl]furo[3,2-b]pyridine;

2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}furo[3,2-b]pyridine;

2-[4-(furo[3,2-b]pyridin-2-ylmethyl)-1-piperazinyl]benzonitrile;

2-{[4-(3-methyl-2-pyridinyl)-1-piperazinyl]methyl}furo[3,2-b]pyridine;

2-[4-(furo[3,2-b]pyridin-2-ylmethyl)-1-piperazinyl]nicotinonitrile;

2-{[4-(2-pyridinyl)-1-piperazinyl]methyl} furo[3,2-b]pyridine;

2-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}furo[3,2-b]pyridine;

2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}[1,3]oxazolo[4,5-b]pyridine;

2-[4-([1,3]oxazolo[4,5-b]pyridin-2-ylmethyl)-1-piperazinyl]benzonitrile;

2-{[4-(2-pyridinyl)-1-piperidinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

2-{[4-(1,3-thiazol-2-yl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

4-{4-[(5-methoxy[1,3]thiazolo[5,4-b]pyridin-2-yl)methyl]-1-piperazinyl}phenol;

2-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}-5-methoxy[1,3]thiazolo[5,4-b]pyridine

5-methoxy-2-({4-[2-(methylthio)phenyl]-1-piperazinyl}methyl)[1,3]thiazolo[5,4-b]pyridine;

5-methoxy-2-{[4-(6-methyl-2-pyridinyl)-1-piperazinyl]methyl}[1,3]thiazol[5,4-b]pyridine;

5-methoxy-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

5-methoxy-2-{[4-(2-pyrimidinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

5-methoxy-2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

2-{[4-(2-chlorophenyl)-1-piperazinyl]methyl}-5-methoxy[1,3]thiazolo[5,4-b]pyridine;

2-{4-[(5-methoxy[1,3]thiazolo[5,4-b]pyridin-2-yl)methyl]-1-piperazinyl}benzonitrile;

2-{[4-(2-chlorophenyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

2-{[4-(6-methyl-2-pyridinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

2-{[4-(5-chloro-2-methoxyphenyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

4-[4-([1,3]thiazolo[5,4-b]pyridin-2-ylmethyl)-1-piperazinyl]phenol;

2-[4-([1,3]thiazolo[5,4-b]pyridin-2-ylmethyl)-1-piperazinyl]nicotinonitrile;

2-({4-[2-(methylthio)phenyl]-1-piperazinyl}methyl)[1,3]thiazolo[5,4-b]pyridine;

2-{[4-(2-pyrimidinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

2-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

2-[4-([1,3]thiazolo[5,4-b]pyridin-2-ylmethyl)-1-piperazinyl]benzonitrile;

2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

2-[(4-phenyl-1-piperazinyl)methyl][1,3]thiazolo[5,4-b]pyridine;

2-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole;

2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole;

2-{[4-(2-pyrimidinyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole;

2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole;

2-[4-(1H-thieno[3,4-d]imidazol-2-ylmethyl)-1-piperazinyl]nicotinonitrile;

4-[4-(1H-thieno[3,4-d]imidazol-2-ylmethyl)-1-piperazinyl]phenol; and

22-({4-[2-(methylthio)phenyl]-1-piperazinyl}methyl)-1H-thieno[3,4-d]imidazoleor a pharmaceutically acceptable salt, ester, amide, N-oxide, or prodrugthereof

Abbreviations

Abbreviations which have been used in the descriptions of the Schemesand the Examples that follow are: Ac for acetyl; BINAP for2,2′-bis(diphenylphosphino)-1,1′-binaphthyl; Boc fortert-butoxycarbonyl; nBuLi for n-butyllithium; dba fordibenzylideneacetone; DCC for 1,3-dicyclohexylcarbodiimide; DCM fordichloromethane; DIEA for diisopropylethylamine; DME for1,2-dimethoxyethane; DMF for N,N-dimethylformamide; DMSO fordimethylsulfoxide; EtOH for ethanol; HPLC for high pressure liquidchromatography; LAH for lithium aluminum hydride; MeOH for methanol; TEAfor triethylamine; Tf for CF₃S(O)₂—; TFA for trifluoroacetic acid; THFfor tetrahydrofuran; TLC for thin layer chromatography.

Preparation of the Present Invention

The compounds and processes of the present invention will be betterunderstood in connection with the following synthetic Schemes andExamples which illustrate a means by which the compounds of the presentinvention can be prepared.

Compounds of general formula (5) and (6), wherein B₁ is as defined informula (I) can be prepared as described in Scheme 1. Piperidinones ofgeneral formula (1), purchased commercially or prepared using standardmethods know to those of skill in the art wherein P is a nitrogenprotecting group such as, but not limited to, (CH₃)₃CO₂C— orC₆H₅CH₂O₂C—, can be treated with compounds of general formula (2),wherein M is Li, MgBr, MgCl, Cu, or Zn to provide compounds of generalformula (3). Compounds of general formula (3) can be treated withBurgess Reagent, thionyl chloride or an acid such as, but not limitedto, sulfuric acid or trifluoracetic acid to provide dihyropyridines ofgeneral formula (4). Dihyropyridines of general formula (4) can bedeprotected using standard methods known to those of ordinary skill inthe art to provide compounds of general formula (5). Compounds ofgeneral formula (4) can also be treated with a metal catalyst such aspalladium on carbon under a hydrogen atmosphere in a solvent such asethyl acetate, ethanol, or methanol to provide compounds of generalformula (6).

Compounds of general formula (5) and (6), wherein B, is as defined informula (I), can be prepared as described in Scheme 2. Piperidinones ofgeneral formula (1), purchased commercially or prepared using standardmethods know to those of skill in the art wherein P is a nitrogenprotecting group such as, but not limited to, (CH₃)₃CO₂C— orC₆H₅CH₂O₂C—, can be treated with Tf₂NPh to provide triflates of generalformula (8). Triflates of general formula (8) can be treated withdiborane pinacol ester to provide boranes of general formula (9).Boranes of general formula (9) can be treated with ArX or HetX in thepresence of a Pd(O) catalyst to provide compounds of general formula(4). Compounds of general formula (4) can be processed as described inScheme 1 to provide compounds of general formula (5) and (6).

Compounds of general formula (14), wherein P, Q, S, T, X, Y, D, and B₁are as defined in formula (I), can be prepared as described in Scheme 3.Fused heterocycles of general formula (11) can be treated withn-butyllithium and paraformaldehyde to provide alcohols of generalformula (12). Alcohols of general formula (12) can be treated withmethane sulfonic anhydride, a base such as, but not limited to, TEA orDIEA, and a compound of formula (13) to provide compounds of formula(14).

Compounds of general formula (18), wherein P, Q, S, T, D, and B₁ are asdefined in formula (I), can be prepared as described in Scheme 4.Anilines of general formula (16), purchased or prepared using standardchemistry known to the art, can be treated with2-chloro-1,1,1-triethoxyethane to provide chloromethyl compounds ofgeneral formula (17). Chloromethyl compounds of general formula (17) canbe treated with compounds of general formula (13) and a base such as,but not limited to, TEA or DIEA to provide compounds of general formula(18).

Compounds of general formula (22) and (23), wherein D and B, are asdefined in formula (I), can be prepared as described in Scheme 5.3,4-Thiophenediamine or 1,3-thiazole-4,5-diamine can be treated with2-chloro-1,1,1-triethoxyethane to provide chloromethyl compounds ofgeneral formula (20) and (21). Chloromethyl compounds of general formula(20) and (21) can be treated with compounds of general formula (13) anda base such as, but not limited to, TEA or DIEA to provide compounds ofgeneral formula (22) and (23).

Compounds of general formula (29), (30), (31), and (32), wherein R_(Y)is as defined in formula (I), can be prepared as described in Scheme 6.Acids of general formula (25), (26), (27), and (28), purchased orprepared using standard methods known to those in the art, can betreated with compounds of general formula (13) and a coupling reagentsuch as, but not limited to, EDCI or DCC to provide the correspondingamides. The amides can be treated with LAH or BH₃ to provide compoundsof general formula (29), (30), (31), and (32).

Compounds of general formula (38), (39), (40), and (41), wherein R_(Y),D, and B₁ are as defined in formula (I), can be prepared as described inScheme 7. Ketones or aldehydes of general formula (34), (35), (36), or(37), purchased or prepared using standard methods known to those in theart, can be treated with compounds of general formula (13) understandard reductive amination conditions known to those in the art suchas, but not limited to, sodium cyanoborohydride or sodiumtriacetoxyborohydride under acidic conditions in a solvent such as butnot limited to, THF, ethanol, or methanol, to provide compounds ofgeneral formula (38), (39), (40), and (41).

The following Examples are intended as an illustration of and not alimitation upon the scope of the invention as defined in the appendedclaims.

EXAMPLE 12-{1-[(5-chloro-1-benzothien-3-yl)methyl]-4-piperidinyl}pyridine

3-(Bromomethyl)-5-chloro-1-benzothiophene (150 mg 0.9 mmol) and4-(2-pyridyl)piperidine (181 mg, 1.0 mmol) were processed as describedin Example 2 to provide the title compound. ¹H NMR (300 MHz, d₆-DMSO) δ2.73 (t, J=1.86 Hz, 4H)) 3.18 (m, 4H) 3.55 (s, 1H) 4.63 (s, 2H) 7.29 (m,2H) 7.50 (dd, J=8.31, 1.86 Hz, 1H) 7.78 (m, 1H) 8.15 (m, 2H) 8.32 (m,1H) 8.53 (s, 1H); (ESI) m/z 343 (M+H)⁺.

EXAMPLE 21-[(5-chloro-1-benzothien-3-yl)methyl]-4-(6-methyl-2-pyridinyl)piperazine

3-(Bromomethyl)-5-chloro-1-benzothiophene (1 mmol, maybridge chemical)and 1-(6-methyl-2-pyridinyl)piperazine (1 mmol) were combined in 2 mL ofacetonitrile and 1 mL of dimethylformamide and stirred at 25° C. for 5minutes. The mixture was heated briefly to dissolve any solids andallowed to cool to 25° C. The mixture was monitored by thin layerchromatography until disappearance of starting residue. The mixture waspoured into dichloromethane and washed with dilute aqueous ammoniumhydroxide. The organic phase was dried over sodium sulfate, filtered,and the filtrate concentrated. The residue was purified by flashchromatography with dichloromethane/methanol/saturated aqueous ammoniato provide the title compound. ¹H NMR (d₆-DMSO, 300 MHz) δ 2.29 (s, 3H),3.31 (m, 6H), 3.45 (m, 2H), 3.74 (s, 2H), 6.48 (d, 1H, J=7.5 Hz), 6.57(d, 1H, J=7.8 Hz), 7.38–7.42 (m, 2H), 7.71 (s, 1H), 8.02 (d, 1H, J=7.8Hz), 8.06 (d, 1H, J=1.5 Hz); MS (DCI/NH₃) m/z 358.1 (M+H)⁺.

EXAMPLE 32-{4-[(5-chloro-1-benzothien-3-yl)methyl]-1-piperazinyl}benzonitrile

3-(Bromomethyl)-5-chloro-1-benzothiophene and2-(1-piperazinyl)benzonitrile were processed as described in Example 2to provide the title compound. ¹H NMR (d₆-DMSO, 300 MHz) δ 3.2–3.65 (m,10H), 7.21 (m, 1H), 7.28 (d, 1H, J=7.8 Hz), 7.51 (dd, 1H, J=7.8,1.5 Hz),7.66 (m, 1H), 7.79 (dd, 1H, J=7.5,1.5 Hz), 8.14 (d, 1H, J=7.8 Hz), 8.25(s, 1H), 8.40 (s, 1H). MS (DCI/NH₃) m/z 368.1 (M+H)⁺.

EXAMPLE 41-[(5-chloro-1-benzothien-3-yl)methyl]-4-(2-pyridinyl)piperazine

3-(Bromomethyl)-5-chloro-1-benzothiophene and 1-(2-pyridinyl)piperazinewere processed as described in Example 2 to provide the title compound.¹H NMR (d₆-DMSO, 300 MHz) δ 3.15 (m, 2H), 3.49 (m, 6H), 3.75 (s, 2H),6.61 (dd, 1H, J=7.5,4.5 Hz), 6.80 (d, 1H, J=8.7 Hz), 7.40 (dd, 1H,J=8.7,1.5), 7.52 (m, 1H), 7.70 (s, 1H), 8.00 (d, 1H, J=8.7 Hz), 8.08 (m,2H). MS (DCI/NH₃) m/z 344.0 (M+H)⁺. Anal. Calcd for C₁₈H₁₈N₃SCl: C,62.87; H, 5.28; N, 12.22. Found: C, 62.71; H, 5.23; N, 12.26.

EXAMPLE 51-[(5-chloro-1-benzothien-3-yl)methyl]-4-(2-fluorophenyl)piperazine

3-(Bromomethyl)-5-chloro-1-benzothiophene and1-(2-fluorophenyl)piperazine were processed as described in Example 2 toprovide the title compound. ¹H NMR (d₆-DMSO, 300 MHz) δ 2.65 (m, 2H),3.02 (m, 6H), 3.78 (s, 2H), 6.92–7.10 (m, 4H), 7.40 (dd, 1H, J=8.7,1.5),7.67 (s, 1H), 7.78 (d, 1H, J=8.7 Hz), 8.06 (d, 1H, J=1.5 Hz). MS(DCI/NH₃) m/z 361.0 (M+H)⁺. Anal. Calcd for C₁₉H₁₈N₂SClF: C, 63.24; H,5.03; N, 7.76. Found: C, 63.17; H, 4.90; N, 7.67.

EXAMPLE 62-{4-[(5-chloro-1-benzothien-3-yl)methyl]-1-piperazinyl}pyrimidine

3-(Bromomethyl)-5-chloro-1-benzothiophene and2-(1-piperazinyl)pyrimidine were processed as described in Example 2 toprovide the title compound. ¹H NMR (CDCl₃, 300 MHz) δ (2.62–2.9 (m, 4H),3.75 (m, 6H), 6.6 (m, 1H), 7.38 (m, 2H), 7.85 (m, 2H), 8.31 (M, 2H). MS(DCI/NH₃) m/z 345.0 (M+H)⁺; Anal. Calcd for C₁₇H₁₇ClN₄S: C, 53.04; H,4.74; N, 14.55. Found: C, 52.79; H, 4.41; N, 14.55.

EXAMPLE 7 1-(1-benzothien-3-ylmethyl)-4-(2-pyridinyl)piperazine

1-Benzothiophene-3-carbaldehyde (6.17 mmole), 1-(2-pyridinyl)piperazine(6.17 mmole), and sodium triacetoxyborohydride (9.26 mmole) werecombined in 25 mL of 1,2-dichloroethane and stirred at 0° C. for onehour. The mixture was allowed to warm to room temperature and stir for12 hours. The mixture was poured into a diethyl ether:dichloromethanemixture and washed with a solution of saturated aqueous NaCl made basicwith sodium hydroxide solution. The organic phase was dried over sodiumsulfate, filtered, and the filtrate concentrated under reduced pressure.The residue was purified by flash chromatography with 96:4:0.5dichloromethane/methanol/saturated aqueous ammonia to provide the titlecompound. ¹H NMR (d₆-DMSO, 300 MHz) δ 2.62 (t, 4H, J=4.5 Hz), 3.51 (t,4H, J=4.5 Hz), 3.82 (s, 2H), 6.65 (m, 1H), 6.80 (d, 1H, J=8.7 Hz), 7.40(m, 2H), 7.48 (s, 1H), 7.53 (m, 1H), 7.86 (m, 1H), 8.04 (m, 2H); MS(DCI/NH₃) m/z 310.0 (M+H)⁺.

EXAMPLE 8 2-[4-(1-benzothien-2-ylmethyl)-1-piperazinyl]benzonitrileEXAMPLE 8A 1-benzothien-2-ylmethanol

Benzothiophene (5.0 g, 37.3 mmol) in anhydrous THF (100 ml) stirring at−20° C. was treated with n-butyllithium (34 ml, 1.6 M, 55.8 mmol) andstirred for 1 hour. The mixture was cooled to −78° C. and treated withparaformaldehyde (7.8 g, 261 mmol) in four portions. The mixture wasallowed to slowly warm to room temperature with stirring overnight. Themixture was treated with 2N HCl (100 ml) and extracted with diethylether (2×100 ml). The organic phases were combined, dried over NaSO₄,filtered, and the filtrate concentrated under reduced pressure. Theresidue was crystallized from DCM/hexanes to provide the title compound.¹H NMR (300 MHz, CDCl₃) δ 4.94 (s, 2H) 7.23 (s, 1H) 7.33 (m, 3H) 7.74(m, 1H); (ESI) m/z 165 (M+H)⁺.

EXAMPLE 8B 2-[4-(1-benzothien-2-ylmethyl)-1-piperazinyl]benzonitrile

The product from Example 8A (150 mg 0.9 mmol), methane sulfonicanhydride (159 mg, 0.9 mmol), and DIEA (475 μL 2.7 mmol) were combined.After stirring, 2-(1-piperazinyl)benzonitrile (181 mg, 1.0 mmol) in 2 mlDCM was also combined and stirred at room temperature for 18 hours. Themixture was concentrated and the residue was taken up in hot methanol.The methanol was filtered and the filter cake washed with cold methanolto provide the title compound. ¹H NMR (300 MHz, CDCl₃) δ 2.69 (m, 4H)3.04 (s, 4H) 3.76 (m, 4H) 3.86 (s, 1H) 6.74 (m, 2H) 7.29 (m, 3H) 7.75(m, 1H); (ESI) m/z 334 (M+H)⁺.

EXAMPLE 9 1-(1-benzothien-2-ylmethyl)-4-(2-fluorophenyl)piperazine

The product from Example 8A (150 mg 0.9 mmol), methane sulfonicanhydride (159 mg, 0.9 mmol), and DIEA (475 μL 2.7 mmol) were combined.After stirring, 1-(2-fluorophenyl)piperazine (181 mg, 1.0 mmol) was alsocombined and processed as described in Example 8B to provide the titlecompound. ¹H NMR (300 MHz, DMSO-d₆) δ 2.63 (m, 4H) 3.04 (m, 4H) 3.86 (s,2H) 7.04 (m, 6H) 7.32 (m, 2H) 7.77 (m, 1H). (ESI) m/z 327 (M+H)⁺.

EXAMPLE 10 1-(1-benzothien-2-ylmethyl)-4-(2-pyridinyl)piperazine

The product from Example 8A (300 mg 1.8 mmol), methane sulfonicanhydride (313 mg, 1.8 mmol), and DIEA (200 μL 5.4 mmol) were combined.After stirring, 1-(2-pyridinyl)piperazine (328 mg, 2.9 mmol) in 4 ml DCMwas also combined and the mixture was processed as described in Example8B to provide the title compound. ₁H NMR (300 MHz, DMSO-d₆) δ 2.57 (m,4H) 3.50 (m, 4H) 3.84 (s, 2H) 6.63 (m, 2H) 6.81 (d, J=8.48 Hz, 1H) 7.32(m, 2H) 7.52 (m, 2H) 7.77 (m, 1H) 7.90 (m, 1H). (ESI) m/z 310 (M+H)⁺.

EXAMPLE 112-{4-[(5-fluoro-1H-indol-2-yl)methyl]-1,4-diazepan-1-yl}benzonitrileEXAMPLE 11A tert-butyl4-[(5-fluoro-1H-indol-2-yl)carbonyl]-1,4-diazepane-1-carboxylate

tert-Butyl 1,4-diazepane-1-carboxylate (2.0 g, 10 mmol, Aldrich),5-fluoro-1H-indole-2-carboxylic acid (1.79 g, 10 mmol, Aldrich), andEDCI (1.92 g, 10 mmol) were combined in CH₂Cl₂ (30 mL) at roomtemperature and stirred for 24 hours. The mixture was concentrated underreduced pressure and the residue was purified by flash chromatography(5% MeOH/CH₂Cl₂) to provide the title compound. ¹H NMR (CD₃OD, 300 MHz)δ 1.46(s, 9H), 1.86–2.14(m, 2H), 3.40–3.58(m, 2H), 3.62–3.72(m, 2H),3.75–4.05(m, 4H), 6.78(s, 1H), 6.99–7.09(m, 1H), 7.28–7.35(m, 2H); MS(DCI/NH3) m/z 362 (M+H)⁺.

EXAMPLE 11B tert-butyl4-[(5-fluoro-1H-indol-2-yl)methyl]-1,4-diazepane-1-carboxylate

The product from Example 11A (0.56 g, 1.60 mmol) in THF (20 mL) wastreated with LAH (4.70 mmol) and stirred at room temperature for 2hours. The mixture was treated with a saturated solution of Na₂SO₄,dried (MgSO₄), filtered and the filtrate was concentrated under reducedpressure to provide the title compound which was used in the next stepwithout further purification. ¹H NMR (CD₃OD, 300 MHz) δ 1.48(s, 9H),1.82–1.95(m, 4H), 2.60–2.68(m, 2H), 3.41–3.56 (m, 4H), 3.75(s, 2H),6.29(s, 1H), 6.85–6.93(m, 1H), 7.12–7.28(m, 2H); MS (DCI/NH3) m/z 348(M+H)⁺.

EXAMPLE 11C 2-(1,4-diazepan-1-ylmethyl)-5-fluoro-1H-indole

The product from Example 11B (0.48 g, 1.40 mmol) in CH₂Cl₂ (20 mL) wastreated with TFA (20 mL) and stirred for 1 hour. The mixture wasconcentrated under reduced pressure and the residue was purified byflash chromatography (10% MeOH/CH₂Cl₂/1% NH₄OH) to provide the titlecompound. ¹H NMR (CD₃OD, 300 MHz) δ 1.85–1.98(m, 4H), 2.58–2.68(m, 2H),3.45–3.57 (m, 4H), 3.67(s, 2H), 6.25(s, 1H), 6.75–6.90(m, 1H),7.10–7.25(m, 2H); MS (DCI/NH3) m/z 248 (M+H)⁺.

EXAMPLE 11D2-{4-[(5-fluoro-1H-indol-2-yl)methyl]-1,4-diazepan-1-yl}benzonitrile

The product from Example 11C (0.38 g, 1.5 mmol) and 2-bromobenzonitrile(0.28 g, 1.5 mmol, Aldrich) in toluene (15 mL) were treated withPd₂(DBA)₃ (0.028 g, 0.04 mmol), BINAP (0.038 g, 0.10 mmol), and CsCO₃(0.99 g, 3.0 mmol) with stirring at 90° C. for 48 hours. The mixture wasallowed to cool to room temperature, filtered, and the filtrate wasconcentrated under reduced pressure. The residue was purified by flashchromatography (5% MeOH/CH₂Cl₂) to provide the title compound. Themaleate salt was formed and recrystallization from ethanol/diethylether. ¹H NMR (CD₃OD, 300 MHz) δ 2.26–2.78 (m, 2H), 3.47–3.55(m, 2H),3.59–3.65(m, 2H), 3.67–3.80(m, 4H), 4.61(s, 2H), 6.75(s, 1H),6.85–7.08(m, 2H), 7.15(d, J=9.0 Hz, 1H), 7.26(dd, J=2.0, 8.0 Hz, 1H),7.36–7.42(m, 1H), 7.50–7.66(m, 2H). m/z 349 (M+H)⁺. Mp 194–198° C. Anal.Calcd for C₂₁H₂₁N₄F.2.4 C₄H₄O₄ 1.0 MeOH: C, 57.59; H, 5.29; N, 8.50.Found: C, 57.91; H, 5.10; N, 8.37.

EXAMPLE 12 2-{1-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-1H-indole

1-(1H-indol-2-yl)ethanone and 1-(2-methoxyphenyl)piperazine wereprocessed as described in Example 7. The residue was purified bypreparative HPLC on a Waters Nova-PakHR C18 column (25 mm×100 mm, 6 umparticle size) using a gradient of 10% to 100% acetonitrile:0.1% aqueousTFA over 8 minutes at a flow rate of 40 mL/minutes to provide the titlecompound. MS (DCI/NH₃) m/z 336 (M+H)⁺.

EXAMPLE 132-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}-1-methyl-1H-indole

1-Methyl-1H-indole-2-carbaldehyde and 1-(2-methoxyphenyl)piperazine wereprocessed as described in Example 7 to provide the title compound. ¹HNMR (CD₃OD, 300 MHz) δ 3.0 (m, 2H), 3.45 (m, 2H), 3.74 (m, 4H), 3.86 (s,3H), 3.88 (s, 2H), 4.70 (s, 3H), 6.83 (s, 1H), 6.90–7.14 (m, 5H), 7.28(m, 1H), 7.48 (d, 1H, J=7.8 Hz), 7.62 (d, 1H, J=7.8 Hz). MS (DCI/NH₃)m/z 336.1 (M+H)⁺. Anal. Calcd for C₂₁H₂₅N₃O: C, 75.19; H, 7.51; N,12.53. Found: C, 74.45; H, 7.43; N, 12.37.

EXAMPLE 14 2-{1-[4-(2-pyridinyl)-1-piperazinyl]ethyl}-1H-indole

1-(1H-indol-2-yl)ethanone and 1-(2-pyridinyl)piperazine were processedas described in Example 7. The residue was purified by preparative HPLCon a Waters Nova-PakHR C18 column (25 mm×100 mm, 6 um particle size)using a gradient of 10% to 100% acetonitrile:0.1% aqueous TFA over 8minutes at a flow rate of 40 mL/minutes to provide the title compound.¹H NMR (CD₃OD, 300 MHz) δ 1.90 (d, 3H, J=6.8 Hz), 3.37 (m, 4H), 3.85 (m,4H), 4.6 (sm, 1H), 6.73 (s, 1H), 6.90 (t, 1H, J=7.8 Hz), 7.06 (m, 2H),7.19 (t, 1H, J=8.1 Hz), 7.43 (d, 1H, J=8.1 Hz), 7.58 (d, 1H, J=8.1 Hz),7.79 (m, 1H), 8.08 (m, 1H); MS (DCI/NH₃) m/z 307 (M+H)⁺.

EXAMPLE 155-fluoro-2-{[(1S,4S)-5-(2-pyridinyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}-1H-indoleEXAMPLE 15A tert-butyl(1S,4S)-5-(2-pyridinyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate

tert-Butyl (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (1.0 g,5.10 mmol, Aldrich) in 1,4-dioxane (10 mL) in a sealed tube was treatedwith 2-bromopyridine (0.40 g, 2.50 mmol, Aldrich) and heated at 150° C.for 12 hours. The mixture was allowed to cool to room temperature andwas concentrated under reduced pressure. The residue was purified byflash chromatography (5% MeOH/CH₂Cl₂) to provide the title compound. ¹HNMR (CDCl₃, 300 MHz) δ 1.48(m, 9H), 1.86–1.94(m, 2H), 3.30–3.58(m, 4H),4.52(brs, 0.5H), 4.67(brs, 0.5H), 4.80(brs, 0.5H), 4.92(brs, 0.5H),6.32(d, J=9.0 Hz, 1H), 6.57(t, J=6.0 Hz, 1H), 7.38–7.55(m, 1H), 8.12(d,J=6.0 Hz, 1H). MS (DCI/NH3) m/z 276 (M+H)⁺.

EXAMPLE 15B (1S,4S)-2-(2-pyridinyl)-2,5-diazabicyclo[2.2.1]heptane

The product from Example 15A (0.52 g, 1.90 mmol) in CH₂Cl₂ (20 mL) wastreated with TFA (20 mL) and stirred for 1 hour. The mixture wasconcentrated under reduced pressure. The residue was purified by flashchromatography (10% MeOH/CH₂Cl₂/1% NH₄OH) to provide the title compound.¹H NMR (CDCl₃, 300 MHz) δ 1.90–1.98(m, 2H), 3.25–3.51(m, 4H),4.50–4.62(m, 2H),6.32(d, J=9.0 Hz, 1H), 6.57(t, J=6.0 Hz, 1H),7.38–7.55(m, 1H), 8.12(d, J=6.0 Hz, 1H); MS (DCI/NH3) m/z 176 (M+H)⁺.

EXAMPLE 15C5-fluoro-2-{[(1S,4S)-5-(2-pyridinyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]carbonyl}-1H-indole

The product from Example 15B (0.40 g, 1.5 mmol) in CH₂Cl₂ (30 mL) wastreated with 5-fluoro-1H-indole-2-carboxylic acid (0.26 g, 1.5 mmol,Aldrich) and EDCI (0.26 g, 1.5 mmol) and stirred at room temperature for24 hours. The mixture was concentrated under reduced pressure. Theresidue was purified by flash chromatography (10% MeOH/CH₂Cl₂) toprovide the title compound. ₁H NMR (CDCl₃, 300 MHz) δ 1.80–2.22(m, 2H),3.10–3.25(m, 2H), 3.35–3.59 (m, 4H), 6.30(m, 1H), 6.50–6.65(m, 1H),6.70(s, 1H), 6.95–7.10(m, 1H), 7.35–7.40(m, 1H), 7.40–7.50(m, 2H),8.10(d, J=8.0 Hz, 1H). m/z 337 (M+H)⁺.

EXAMPLE 15D5-fluoro-2-{[(1S,4S)-5-(2-pyridinyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}-1H-indole

The product from Example 15C in THF solution (30 mL) was treated withLAH (5.50 mmol) and stirred at room temperature for 2 hours. The mixturewas treated with Na₂SO₄ decahydrate, filtered and the filtrateconcentrated under reduced pressure. The residue was purified by flashchromatography (10% MeOH/CH₂Cl₂) to provide the title compound. Themaleate salt was formed and recrystallization from ethanol/diethylether. ¹H NMR (CD₃OD, 300 MHz) δ 2.22–2.36(m, 2H), 3.45–3.62(m, 2H),3.70(s, 2H), 4.45–4.58(m, 3H), 4.85(s, 1H), 6.23(s, 1H), 6.62–6.65(m,1H), 6.70(t, J=3.0 Hz, 1H), 6.95(dt, J=2.0, 6.0 Hz, 1H), 7.22(dd, J=2.0,8.0 Hz, 1H), 7.40–7.45(m, 1H), 7.60(t, J=2.0 Hz, 1H), 8.05(d, J=2.0 Hz,1H); MS (DCI/NH3) m/z 322 (M+H)⁺. Mp 211–214° C. Anal. Calcd forC₁₉H₁₉N₄F.1.3 C₄H₄O₄: C, 61.82; H, 5.36; N, 11.38. Found: C, 61.88; H,4.99; N, 11.28.

EXAMPLE 165-fluoro-2-{[4-(2-pyridinyl)-1,4-diazepan-1-yl]methyl}-1H-indole EXAMPLE16A tert-butyl 4-(2-pyridinyl)-1,4-diazepane-1-carboxylate

tert-Butyl 1,4-diazepane-1-carboxylate (5.0 g, 25.0 mmol) (Aldrich) and2-bromopyridine (1.98 g, 12.50 mmol) (Aldrich) were combined in a sealedtube and heated at 150° C. for 12 hours. The mixture was purified byflash chromatography (5% MeOH/CH₂Cl₂) to provide the title compound. ¹HNMR (CDCl₃, 300 MHz) δ 1.48(m, 9H), 1.88–2.02(m, 2H), 3.20–3.48(m, 2H),3.52–3.70(m, 4H), 3.72–3.83(m, 2H), 6.45–6.59(m, 2H), 7.47(m, 2H),8.11–8.18(m, 1H); MS (DCI/NH3) m/z 278 (M+H)⁺.

EXAMPLE 16B 1-(2-pyridinyl)-1,4-diazepane

The product from Example 16A (1.0 g, 4.00 mmol) in CH₂Cl₂ (10 mL) wastreated with TFA (10 mL) and stirred for 1 hour. The mixture wasconcentrated under reduced pressure. The residue was purified by flashchromatography (10% MeOH/CH₂Cl₂/1% NH₄OH) to provide the title compound.¹H NMR (CDCl₃, 300 MHz) δ 1.85–2.00(m, 2H), 3.25–3.43(m, 2H),3.50–3.43(m, 2H), 3.50–3.83(m, 6H), 6.52–6.60(m, 2H), 7.45(m, 1H),8.00(m, 1H); MS (DCI/N3) m/z 178 (M+H)⁺.

EXAMPLE 16C5-fluoro-2-{[4-(2-pyridinyl-1,4-diazepan-1-yl]carbonyl}-1H-indole

The product from Example 16B (0.68 g, 3.8 mmol) in CH₂Cl₂ (25 mL) wastreated with 5-fluoro-1H-indole-2-carboxylic acid (0.68 g, 3.8 mmol,Aldrich) and EDCI (0.73 g, 3.8 mmol) and stirred at room temperature for48 hours. The mixture was concentrated under reduced pressure. Theresidue was purified by flash chromatography (10% MeOH/CH₂Cl₂) toprovide the title compound. ¹H NMR (CDCl₃, 300 MHz) δ 2.01–2.22(m, 2H),3.65–4.21(m, 8H), 6.56(d, J=9.0 Hz, 2H), 6.78(s, 1H), 7.10(t, J=3.0 Hz,1H), 7.27–7.39(m, 2H), 7.42(t, J=3.0 Hz, 1H), 8.10–8.20(m, 1H); MS(DCI/NH3) m/z 338 (M+H)⁺.

EXAMPLE 16D5-fluoro-2-{[4-(2-pyridinyl)-1,4-diazepan-1-yl]methyl}-1H-indole

The product from Example 16C in THF solution (10 mL) was treated withLAH (0.90 mmol of 1M) and stirred at room temperature for 2 hours. Themixture was treated with Na₂SO₄ decahydrate, filtered, and the filtrateconcentrated under reduced pressure. The residue was purified by flashchromatography (10% MeOH/CH₂Cl₂) to provide the title compound. Themaleate salt was formed and recrystallization from ethanol/diethyl etheras a white solid. ¹H NMR (CD₃OD, 300 MHz) δ 2.23–2.32(m, 2H),3.35–3.47(m, 4H), 3.67(t, J=9.0 Hz, 2H), 3.97–4.08(m, 2H), 4.45(s, 2H),6.25(s, 1H), 6.63–6.81(m, 2H), 6.98(dt, J=2.0, 6.0 Hz, 1H), 7.22(dd,J=2.0, 6.0 Hz, 1H), 7.33–7.42(m, 1H), 7.60(t, J=6.0 Hz, 1H), 8.08(d,J=3.0 Hz, 1H).MS (DCI/NH3) m/z 325 (M+H)⁺. Anal. Calcd for C₁₉H₂₁N₄F.1.2C₄H₄O₄: C, 60.28; H, 5.59; N, 12.33. Found: C, 60.52; H, 5.65; N, 12.62

EXAMPLE 17 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indoleEXAMPLE 17A5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}-1H-indole

5-Fluoro-1H-indole-2-carboxylic acid (4.0 g) and EDCI (4.29 g) werecombined in dichloromethane (90 mL) and treated with1-(2-pyridinyl)piperazine (3.64 g). After stirring at 25° C. for 24hours, the mixture was washed with 150 mL of water and filtered. Thefilter cake was washed in succession with 300 mL of water, 250 mL ofdichloromethane and 20 mL of ethyl acetate to provide the titlecompound. ¹H NMR (d₆-DMSO, 300 MHz) δ 3.61 (m, 4H), 3.85 (m, 4H), 6.67(dd, 1H, J=7.5,4.8 Hz), 6.85 (m, 2H), 7.06 (m, 1H), 7.40 (m, 2H), 7.65(m, 1H), 8.04 (dd, 1H, J=4.5,1.8 Hz), 11.72 (bs, 1H). MS (DCI/NH₃) m/z325 (M+H)⁺.

EXAMPLE 17B 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole

The product from Example 17A (3.50 g) in tetrahydrofuran (50 mL) wastreated with lithium aluminum hydride (30 mmol). The mixture was wastreated by sequential addition of 1.14 mL of water, 1.14 mL of 15%aqueous sodium hydroxide, and 3.42 mL of water. The slurry was filteredand the filtrate diluted with ethanol and then concentrated underreduced pressure. The residue was filtered through a plug of silica gel,then purified by chromatography on silica gel, eluting with ethylacetate containing 0.1% ammonium hydroxide to provide the titlecompound. ¹H NMR (d₆-DMSO, 300 MHz) δ 2.55 (m, 4H), 3.50 (t, 4H, J=4.5Hz), 3.65 (s, 2H), 6.30 (s, 1H), 6.63 (dd, 1H, J=7.5,4.8 Hz), 6.80 (d,1H, J=7.5 Hz), 6.85 (m, 1H), 7.20 (dd, 1H, J=10.5,2.4 Hz), 7.30 (dd, 1H,J=9, 5.4 Hz), 7.50 (m, 1H), 8.09 (dd, 1H, J=4.5,1.8 Hz), 11.72 (bs, 1H).MS (DCI/NH₃) m/z 311 (M+H)⁺. The free base was dissolved in 45 mL ofmethanol, along with 1.0 equivalent of maleic acid. Addition of toluene,then evaporation under reduced pressure gave a glass, which was coveredwith 25 mL of ether, which yielded crystals when a small amount ofmethanol was added. Evaporation of solvent, followed byrecrystallization of the resulting solid from 15 mL of methanol, 15 mLof toluene, and 200 mL of ether, gave 3.11 g (88% from the free base) of5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole maleate.Anal. Calcd for C₁₈H₁₉N₄F.C₄H₄O₄: C, 61.96; H, 5.44; N, 13.14. Found: C,61.89; H, 5.36; N, 13.12.

EXAMPLE 182-[4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1-piperazinyl]benzonitrile

1H-pyrrolo[2,3-b]pyridine (47 mg, 0.40 mmol),2-(1-piperazinyl)benzonitrile (65 mg, 0.48 mmol), sodium acetate (72 mg,0.53 mmol), and formaldehyde (0.48 mmol) were combined in water andglacial acetic acid (1:2, 1 mL) and stirred at room temperature for 18hours. The mixture was treated with a solution of 2M NaOH andconcentrated under reduced pressure. The residue was treated with hotmethanol. The methanol was filtered and the filter cake was washed withcold methanol to provide the title compound. ¹H NMR (300 MHz, DMSO-d₆) δ2.62 (m, 4H) 3.14 (m, 4H) 4.03 (s, 2H) 5.60 (s, 1H) 7.09 (m, 3H) 7.61(m, 2H) 8.06 (dd, J=8.31, 1.53 Hz, 1H) 8.20 (dd, J=4.75, 1.70 Hz, 1H).(ESI) m/z 318 (M+H)⁺.

EXAMPLE 193-(4-Pyrimidin-2-yl-piperazin-1-ylmethyl)-1H-pyrrolo[2,3-b]pyridin

1H-pyrrolo[2,3-b]pyridine (47 mg, 0.40 mmol),2-(1-piperazinyl)pyrimidine (65 mg, 0.48 mmol), sodium acetate (72 mg,0.53 mmol), and formaldehyde (0.48 mmol) were processed as described inExample 18 to provide the title compound. ¹H NMR (300 MHz, DMSO-d₆) δ2.42 (m, 4H) 3.68 (m, 4H) 4.05 (s, 2H) 5.59 (s, 1H) 6.60 (m, 1H) 7.08(m, 2H) 7.37 (m, 2H 8.07 (m, 2H). (ESI) m/z 295 (M+H)⁺.

EXAMPLE 203-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}-1H-pyrrolo[2,3-b]pyridine

1H-pyrrolo[2,3-b]pyridine (47 mg, 0.40 mmol),1-(2-methoxyphenyl)piperazine (65 mg, 0.48 mmol), sodium acetate (72 mg,0.53 mmol), and formaldehyde (0.48 mmol) were processed as described inExample 18 to provide the title compound. ¹H NMR (300 MHz, DMSO-d₆) δ2.97 (m, 4H) 3.68 (m, 4H) 3.72 (s, 3H) 4.05 (s, 2H) 5.60 (m, 1H) 6.60(m, 1H), 6.89 (m, 2H) 7.08 (ddd, J=21.36, 7.80, 4.75 Hz, 1H) 7.52 (m,2H) 8.07 (m, 2H) (ESI) m/z 323 (M+H)⁺.

EXAMPLE 213-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-pyrrolo[2,3-b]pyridine

1H-pyrrolo[2,3-b]pyridine (47 mg, 0.40 mmol), 1-(2-pyridinyl)piperazine(65 mg, 0.48 mmol), sodium acetate (72 mg, 0.53 mmol), and formaldehyde(0.48 mmol) were processed as described in Example 18 to provide thetitle compound. ¹H NMR (300 MHz, DMSO-d₆) δ 2.49 (m, 4H) 3.45 (m, 4H)3.67 (s, 2H)5.59 (s, 1H) 6.60 (dd, J=6.78, 5.09 Hz, 1H) 6.77 (d, J=8.82Hz, 1H) 7.04 (dd, J=7.97, 4.58 Hz, 1H) 7.49 (m, 2H) 8.06 (m, 1H) 8.19(dd, J=4.75, 1.70 Hz, 1H) (ESI) 294 m/z (M+H)⁺.

EXAMPLE 22 3-[(4-phenyl-1-piperazinyl)methyl]-1H-pyrrolo[2,3-b]pyridine

1H-pyrrolo[2,3-b]pyridine (47 mg, 0.40 mmol), 1-phenylpiperazine (64.9mg, 0.48 mmol), sodium acetate (72 mg, 0.53 mmol), and formaldehyde(0.48 mmol) were processed as described in Example 18 to provide thetitle compound. ¹H NMR (300 MHz, DMSO-d₆) δ 2.62 (m, 4H) 3.14 (m, 4H)4.03 (s, 2H) 5.60 (s, 1H) 7.09 (m, 3H) 7.84 (m, 3H) 8.06 (dd, J=8.31,1.53 Hz, 1H) 8.20 (dd, J=4.75, 1.70 Hz, 1H). (ESI) m/z 293 (M+H)⁺.

EXAMPLE 233-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}-1H-pyrrolo[2,3-b]pyridine

1H-pyrrolo[2,3-b]pyridine (47 mg, 0.40 mmol),1-(2-flurophenyl)piperazine (72.0 mg, 0.48 mmol), sodium acetate (72 mg,0.53 mmol), and formaldehyde (0.48 mmol) were processed as described inExample 18 to provide the title compound. ¹H NMR (300 MHz, DMSO-d₆) δ2.62 (m, 4H) 3.14 (m, 4H) 4.03 (s, 2H) 5.60 (s, 1H) 7.09 (m, 3H) 7.14(m, 2H) 8.06 (dd, J=8.31, 1.53 Hz, 1H) 8.20 (dd, J=4.75, 1.70 Hz, 1H).(ESI) m/z 311 (M+H)⁺.

EXAMPLE 242-[4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1-piperazinyl]nicotinonitrile

1H-pyrrolo[2,3-b]pyridine (47 mg, 0.40 mmol),2-(1-piperazinyl)nicotinonitrile (75 mg, 0.48 mmol), sodium acetate (72mg, 0.53 mmol), and formaldehyde (0.48 mmol) were processed as describedin Example 18 to provide the title compound. ¹H NMR (300 MHz, DMSO-d₆) δ2.57 (m, 4H) 3.50 (m, 4H) 3.84 (s, 2H) 6.63 (m, 2H) 6.81 (m, 1H) 7.32(m, 1H) 7.52 (m, 1H) 7.77 (m, 1H) 7.90 (m, 1H). (ESI) m/z 319 (M+H)⁺.

EXAMPLE 254-(4-{[6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]methyl}-1-piperazinyl)phenolEXAMPLE 25A ethyl 6-(trifluoromethyl)thieno[3,2-b]pyridine-2-carboxylate

3-Chloro-5-(trifluoromethyl)-2-pyridinecarbaldehyde (Chemical Abstractsnumber 175277-50-6, purchase from Maybridge), potassium carbonate (4.95g), and ethyl mercaptoacetate (2.52 g) were combined inN,N-dimethylformamide (25 mL) at 25° C. and stirred for 18 hours. Themixture was then heated at 50° C. for 6 hours, allowed to cool to roomtemperature, poured into a mixture of diethyl ether (80 mL) anddichloromethane (25 mL), and washed with aqueous sodium carbonate. Theorganic phase was dried over sodium sulfate, filtered, and the filtrateconcentrated under reduced pressure. The residue was dissolved indichloromethane and filtered to remove solids. The filtrate wasconcentrated and the residue purified by flash chromatography(dichloromethane) to provide the title compound. MS (DCI/NH₃) m/z 276.0(M+H)⁺.

EXAMPLE 25B [6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]methanol

The product from Example 25A (2.80 g) in tetrahydrofuran (20 mL) andethanol (20 mL) was treated with sodium borohydride (0.388 g) at 25° C.After stirring for 24 hours, the mixture was treated with additionalsodium borohydride (1 g) and additional ethanol. After an additional 24hours, the mixture was poured into 0.2% NH₄OH (200 mL) and extractedwith dichloromethane. The organic phase was washed with water andconcentrated under reduced pressure. The residue was purified by flashchromatography (97:3:0.1 dichloromethane:methanol:sat. NH₄OH solution)to provide the title compound. ¹H NMR (CDCl₃, 300 MHz) δ 5.02 (s, 2H),7.48 (s, 1H), 8.36 (s, 1H), 8.87 (s, 1H). MS (DCI/NH₃) m/z 234 (M+H)⁺.

EXAMPLE 25C [6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]methylmethanesulfonate

The product from Example 25B (732 mg) and methanesulfonic anhydride (547mg) were combined and cooled to 0° C. The mixture was treated withdichloromethane (22 mL) and N,N-diisopropylethylamine (0.66 mL). After30 minutes, the solution was used to in the next step.

EXAMPLE 25D4-(4-{[6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]methyl}-1-piperazinyl)phenol

The solution from Example 25C (2 mL) was treated with4-(1-piperazinyl)phenol (178 mg) in DMSO (1 mL). After 72 hours, themixture was concentrated under a stream of nitrogen gas and the residuerecrystallized from DMSO:methanol (1:1) to provide the title compound.¹H NMR (CDCl₃, 300 MHz) δ 2.81 (4H, t, J=4.8 Hz), 3.18 (4H, J=4.8 Hz),3.95 (s, 2H), 6.78 (2H, d, J=9 Hz), 6.90 (2H, J=9 Hz), 7.48 (1H, s),8.38 (1H, m), 8.80 (1H, m). MS (DCI/NH₃) m/z 394 (M+H)⁺. Anal. Calcd forC₁₉H₁₈N₃F₃OS: C, 56.72; H, 4.76; N, 10.44. Found: C, 56.43; H, 4.50; N,10.35.

EXAMPLE 262-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}-6-(trifluoromethyl)thieno[3,2-b]pyridine

The solution from Example 25C (2 mL) and 1-(2-methoxyphenyl)piperazine(192 mg) were processed as described in Example 25D to provide the titlecompound. ¹H NMR (CDCl₃, 300 MHz) δ 3.11 (4H, t, J=4.8 Hz), 3.45 (4H,J=4.8 Hz), 4.19 (s, 3H), 4.30 (s, 2H), 6.90 (4H, m), 7.80 (1H, s), 8.63(1H, m), 9.20 (1H, m). MS (DCI/NH₃) m/z 408.2 (M+H)⁺. Anal. Calcd forC₂₀H₂₀N₃F₃OS: C, 58.96; H, 4.95; N, 10.31. Found: C, 58.98; H, 4.95; N,10.53.

EXAMPLE 272-(4-{[6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]methyl}-1-piperazinyl)benzonitrile

The solution from Example 25C (2 mL) and 2-(1-piperazinyl)benzonitrile(187 mg) were processed as described in Example 25D to provide the titlecompound. ¹H NMR (CDCl₃, 300 MHz) δ 2.81 (4H, t, J=4.8 Hz), 3.29 (4H,J=4.8 Hz), 4.00 (s, 2H), 7.03 (2H, m), 7.50 (2H, m), 7.59 (dd, 1H,J=7.5,1.5 Hz), 8.39 (1H, m), 8.86 (1H, m). MS (DCI/NH₃) m/z 403.1(M+H)⁺. Anal. Calcd for C₂₀H₁₇N₄F₃S: C, 59.69; H, 4.26; N, 13.92. Found:C, 59.53; H, 4.12; N, 14.22.

EXAMPLE 28 4-[4-(furo[3,2-b]pyridin-2-ylmethyl)-1-piperazinyl]phenol

The product from Example 35B, 4-(1-piperazinyl)phenol, and sodiumtriacetoxyborohydride were processed as described in Example 35C toprovide the title compound. ¹H NMR (CDCl₃, 300 MHz) δ 2.83 (br, 4H),3.16 (br, 4H), 3.88 (s, 2H), 6.77 (m, J=2.03, 8.81 Hz, 2H), 6.89 (m,3H), 7.25 (dd, J=4.75, 8.48 Hz, 1H), 7.80 (d, J=8.48 Hz, 1H), 8.48 (m,J=1.02, 8.48 Hz, 1H); MS (DCI/NH₃) m/z 310.1 (M+H)⁺.

EXAMPLE 29 2-[(4-phenyl-1-piperazinyl)methyl]furo[3,2-b]pyridine

The product from Example 35B, 1-phenylpiperazine, and sodiumtriacetoxyborohydride were processed as described in Example 35C toprovide the title compound. ¹H NMR (CDCl₃, 300 MHz) δ 2.78 (br, 4H),3.28 (br, 4H), 3.85 (s, 2H), 6.89 (m, 4H), 7.20 (dd, J=4.75, 8.14 Hz,1H), 7.26 (m, 2H), 7.73 (d, J=8.14 Hz, 1H), 8.54 (br, 1H); MS (DCI/NH₃)m/z 294.2 (M+H)⁺; Anal Calcd for C₁₈H₁₉N₃O: C, 73.69; H, 6.53; N, 14.32.Found: C, 72.19; H, 6.43; N, 14.09.

EXAMPLE 302-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}furo[3,2-b]pyridine

The product from Example 35B, 1-(2-methoxyphenyl)piperazine, and sodiumtriacetoxyborohydride were processed as described in Example 35C toprovide the title compound. ¹H NMR (CDCl₃, 300 MHz) δ 2.85 (br, 4H),3.19 (br, 4H), 3.85 (s, 3H), 3.88 (s, 2H), 6.93 (m, 5H), 7.20 (dd, 4.75,8.14 Hz, 1H), 7.74 (m, J=1.02, 7.12 Hz, 1H), 8.54 (br, 1H); MS (DCI/NH₃)m/z 324.2 (M+H)⁺; Anal Calcd for C₁₉H₂₁N₃O₂: C, 70.57; H, 6.55; N,12.99. Found: C, 69.72; H, 6.45; N, 12.81.

EXAMPLE 312-[4-(furo[3,2-b]pyridin-2-ylmethyl)-1-piperazinyl]benzonitrile

The product from Example 35B, 2-(1-piperazinyl)benzonitrile, and sodiumtriacetoxyborohydride were processed as described in Example 35C toprovide the title compound. ¹H NMR (CDCl₃, 400 MHz) δ 2.87 (m, 4H), 3.32(m, 4H), 3.89 (s, 2H), 6.92 (s, 1H), 7.02 (m, 2H), 7.20 (dd, J=4.60,8.29 Hz, 1H), 7.48 (m, J=1.84, 7.24, 8.65 Hz, 1H), 7.56 (dd, J=1.84,7.98 Hz, 1H), 7.75 (m, J=1.23, 8.29 Hz, 1H), 8.53 (dd, J=1.23, 4.91 Hz,1H); MS (DCI/NH₃) m/z 319.2 (M+H)⁺; Anal Calcd for C₁₉H₁₈N₄O: C, 71.68;H, 5.70; N, 17.60. Found: C, 70.87; H, 5.90; N, 17.01.

EXAMPLE 322-{[4-(3-methyl-2-pyridinyl)-1-piperazinyl]methyl}furo[3,2-b]pyridine

The product from Example 35B, 1-(3-methyl-2-pyridinyl)piperazine, andsodium triacetoxyborohydride were processed as described in Example 35Cto provide the title compound. ¹H NMR (CDCl₃, 300 MHz) δ 2.68 (m, 4H),3.29 (s, 3H), 3.58 (m, 4H), 3.79 (s, 2H), 6.41 (d, J=8.48 Hz, 1H), 6.49(d, J=7.12 Hz, 1H), 6.85 (s, 1H), 7.18 (dd, J=4.75, 8.14 Hz, 1H) 7.36(dd, J=7.12, 8.14 Hz, 1H), 7.73 (dd, J=1.02, 8.14 Hz, 1H), 8.51 (dd,J=1.36, 4.75 Hz, 1H); MS (DCI/NH₃) m/z 309.2 (M+H)⁺.

EXAMPLE 332-[4-(furo[3,2-b]pyridin-2-ylmethyl)-1-piperazinyl]nicotinonitrile

The product from Example 35B, 2-(1-piperazinyl)nicotinonitrile, andsodium triacetoxyborohydride were processed as described in Example 35Cto provide the title compound. ¹H NMR (CDCl₃, 300 MHz) δ 2.78 (br, 4H),3.82 (br, 6H), 6.75 (dd, J=4.75, 7.80 Hz, 1H), 6.90 (s, 1H), 7.21 (dd,J=4.75, 8.14 Hz, 1H), 7.75 (m, J=1.02, 8.14 Hz, 1H), 7.77 (dd, 2.03,7.46 Hz, 1H), 8.33 (dd, J=2.03, 4.75 Hz, 1H), 8.54 (d, J=4.41 Hz, 1H);MS (DCI/NH₃) m/z 320.3 (M+H)⁺.

EXAMPLE 34 2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}furo[3,2-b]pyridine

The product from Example 35B, 1-(2-pyridinyl)piperazine, and sodiumtriacetoxyborohydride were processed as described in Example 35C toprovide the title compound. ¹H NMR (CDCl₃, 300 MHz) δ 2.71 (br, 4H),3.63 (br, 4H), 3.81 (s, 2H), 6.63 (m, 1H), 6.65 (d, J=8.48 Hz), 6.87 (s,1H), 7.19 (dd, J=4.75, 8.14 Hz, 1H), 7.47 (m, J=2.03, 7.12, 8.48 Hz,1H), 7.72 (d, J=8.48 Hz, 1H), 8.18 (m, J=2.03, 5.09 Hz, 1H), 8.52 (d,J=4.07 Hz, 1H); MS (DCI/NH₃) m/z 295.2 (M+H)⁺; Anal Calcd for C₁₇H₁₈N₄O:C, 69.37; H, 6.16; N, 19.03. Found: C, 69.38; H, 5.96; N, 18.89.

EXAMPLE 352-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}furo[3,2-b]pyridine EXAMPLE35a 2-(diethoxymethyl)furo[3,2-b]pyridine

2-Iodo-3-pyridinol (24 mmol), triethylamine (1.0 eq),3,3-diethoxy-1-propyne (1.0 eq), bis(triphenylphosphine)palladium (II)chloride (0.02 eq), and copper(I) iodide (0.04 eq) were combined in DMF(14 mL) and allowed to stir for 17 hours. The mixture was diluted withethyl acetate (100 mL) and filtered through a Celite pad. The filtratewas washed with saturated sodium bicarbonate (2×50 mls), dried overanhydrous magnesium sulfate, filtered, and the filtrate concentratedunder reduced pressure to provide the title compound which was used inthe next step without further purification. ¹H NMR (CDCl₃, 400 MHz) δ1.28 (t, J=7.1 Hz, 6H), 3.70 (q, J=7.1 Hz, 4H), 5.68 (s, 1H), 7.05 (s,1H), 7.23 (dd, J=8.5, 4.8 Hz, 1H), 7.77 (d, J=8.5 Hz, 1H), 8.57 (br,1H). MS (DCI/NH₃) m/z 222 (M+H)⁺.

EXAMPLE 35B furo[3,2-b]pyridine-2-carbaldehyde

The product from Example 35A (5.6 g, 25 mmol) in THF (50 mL) and water(10 mL) was treated with trifluoroacetic acid (10 mL) and heated at 60°C. for 17 hours. The mixture was allowed to cool to room temperature,treated with water (200 mL), treated with sodium bicarbonate slowly tobring the pH to 8.0, and extracted with dichloromethane (100 mL). Theorganic phase was dried over anhydrous magnesium sulfate, filtered, andthe filtrate concentrated under reduced pressure. The residue waspurified by flash chromatography on silica (5% methanol indichloromethane) to provide the title compound. ¹H NMR (CDCl₃, 400 MHz)δ 7.45 (dd, J=4.75, 8.48 Hz, 1H), 7.77 (s, 1H), 7.93 (dd, J=1.02, 8.48Hz, 1H), 8.73 (dd, J=1.02, 4.75 Hz, 1H), 9.98 (s, 1H); MS (DCI/NH₃) m/z148.0 (M+H)⁺.

EXAMPLE 35C2-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}furo[3,2-b]pyridine

1-(2-Fluorophenyl)piperazine (0.18 g, 1.0 mmol) and sodiumtriacetoxyborohydride (0.32 g, 1.5 mmol) in dichloroethane (2 mL) weretreated with the product from Example 35B (2 mL, 1.0 mmol) as a 0.5Msolution in dichloroethane dropwise. The mixture was allowed to stir atroom temperature for 17 hours. The mixture was diluted withdichloromethane (10 mL) and washed with 1N NaOH. The organic layer wasdried over magnesium sulfate, filtered, and the filt0rate concentratedunder reduced pressure. The residue was purified by flash chromatographyon silica (dichloromethane to 2% methanol in dichloromethane) to providethe title compound. ¹H NMR (CDCl₃, 400 MHz) δ 2.81 (br, 4H), 3.19 (br,4H), 3.85 (s, 2H), 6.89 (s, 1H), 7.00 (m, 4H), 7.20 (dd, J=4.75, 8.14Hz, 1H), 7.74 (d, J=8.48 Hz, 1H), 8.52 (d, J=4.75 Hz 1H); MS (DCI/NH₃)m/z 312.2 (M+H)⁺; Anal. Calcd for C₁₈H₁₈FN₃O: C, 69.44; H, 5.83; N,13.50. Found: C, 69.36; H, 5.59; N, 13.28.

EXAMPLE 362-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}[1,3]oxazolo[4,5-b]pyridineEXAMPLE 36A 2-(chloromethyl)[1,3]oxazolo[4,5-b]pyridine

2-Amino-3-pyridinol (1.1 g, Chemical Abstracts #16867-03-1) andchloromethyltrimethylorthoformate (2.27 g) were combined in diglyme (in21 mL) and heated at 80° C. for 6 hours. The mixture was treated withp-toluenesulfonic acid hydrate (4 mg) and heated at 80° C. for anadditional 48 hours. The mixture was allowed to cool to room temperatureand diluted with chloroform (40 mL) and ethanol (10 mL). The mixture wasfiltered and the filtrate concentrated under reduced pressure. Theresidue was dissolved in methanol and filtered again. The resultingfiltrate was concentrated under reduced pressure to provide the titlecompound and then dissolved in acetonitrile (35 mL) and used as asolution in the next step. ¹H NMR (CDCl₃, 300 MHz) δ 4.82 (2H, s), 7.38(dd, 1H, J=8.7, 5.4 Hz), 7.89 (dd, 1H, J=8.7, 1.5 Hz), 8.62 (dd, 1H,J=5.4, 1.5 Hz). MS (DCI/NH₃) m/z 169 (M+H)⁺.

EXAMPLE 36B2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}[1,3]oxazolo[4,5-b]pyridine

The solution from Example 36A (7 mL) was treated with1-(2-methoxyphenyl)piperazine (160 mg) and stirred at 25° C. for 12hours. The mixture was poured into aqueous sodium chloride solution andextracted with dichloromethane:n-butanol (5:1). The organic phase wasconcentrated under reduced pressure and the residue was purifed by flashchromatography on silica gel (98:2:0.1 dichloromethane:methanol:NH₄OH)to provide the title compound. ¹H NMR (CDCl₃, 300 MHz) δ 2.95 (4H, m),3.21 (4H, m), 3.85 (3H, s), 4.2 (2H, m), 6.88–7.1 (4H, m), 7.40 (1H, m),7.91 (1H, m), 8.55 (1H, m). MS (DCI/NH₃) m/z 325.2 (M+H)⁺. Anal. Calcdfor C₁₈H₂₀N₄O₂(0.3H₂O): C, 65.56; H, 6.30; N, 16.99. Found: C, 65.61; H,6.09; N, 16.98.

EXAMPLE 372-[4-([1,3]oxazolo[4,5-b]pyridin-2-ylmethyl)-1-piperazinyl]benzonitrile

The solution from Example 36A (7 mL) and 2-(1-piperazinyl)benzonitrile(260 mg) were processed as described in Example 36B. ¹H NMR (CDCl₃, 300MHz) δ 2.95 (4H, m), 3.32 (4H, m), 4.10 (2H, s), 7.08 (2H, m), 7.38 (dd,1H, J=8.7, 5.4 Hz), 7.55 (2H, m), 7.91 (dd, 1H, J=8.7, 1.5 Hz), 8.55(dd, 1H, J=5.4, 1.5 Hz); MS (DCI/NH₃) m/z 320.2 (M+H)⁺.

EXAMPLE 382-{[4-(2-pyridinyl)-1-piperidinyl]methyl}[1,3]thiazolo[5,4-]pyridineEXAMPLE 38A 2-(chloromethyl)[1,3]thiazolo[5,4-b]pyridine

3-Amino-2-pyridinethiol (5.0 g, 39.6 mmol) and2-chloro-1,1,1-triethoxyethane (8.57 g, 43.5 mmol) were combined inabsolute ethanol (40 mL) and refluxed for 2 hours. The mixture wasconcentrated under reduced pressure and the residue purified by flashchromatography (ethyl acetate:hexanes, 1:4) to provide the titlecompound. ¹H NMR (300 MHz, CDCl₃) δ 4.93 (s, 2H) 7.47 (dd, J=8.14, 4.75Hz, 1H) 8.26 (dd, J=8.31, 1.53 Hz, 1H) 8.62 (dd, J=4.58, 1.53 Hz, 1H).(ESI) m/z 186 (M+H)⁺.

EXAMPLE 38B2-{[4-(2-pyridinyl)-1-piperidinyl]methyl}[1,3]thiazolo[5,4-b]pyridine

The product from Example 38A (50 mg, 0.11 mmol),2-(4-piperidinyl)pyridine (25 mg, 0.13 mmol), and DIEA (340 μL, 2.1mmol) were combined in acetonitrile (1 mL) and stirred at roomtemperature for 18 hours. The reaction mixture was concentrated underreduced pressure. The residue was treated with hot methanol. Themethanol was filtered and the filter cake washed with cold methanol toprovide the title compound. ¹H NMR (300 MHz, DMSO-d₆) δ 2.13 (m, 4H),3.13 (m, 4H), 3.61 (m, 3H), 7.38 (d, J=4.75 Hz, 1H), 7.76(dd, J=8.3 Hz,4.6 Hz, 1H), 7.91 (m, 1H), 8.31 (m, 1H), 8.54 (m, 2H), 8.72 (dd, J=4.6hz, 1.53 Hz, 1H); (ESI) m/z 311 (M+H)⁺.

EXAMPLE 392-{[4-(1,3-thiazol-2-yl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine

The product from Example 38A (200 mg, 1.1 mmol),1-(1,3-thiazol-2-yl)piperazine (219 mg, 1.3 mmol), and DIEA (340 μL, 2.1mmol) were processed as described in Example 38B to provide the titlecompound. ¹H NMR (300 MHz, DMSO-d₆) δ 2.71 (m, 4H) 3.46 (m, 4H) 4.06 (s,2H) 6.86 (d, J=3.73 Hz, 1H) 7.17 (d, J=3.73 Hz, 1H) 7.56 (dd, J=8.14,4.75 Hz, 1H) 8.33 (dd, J=8.14, 1.70 Hz, 1H) 8.59 (dd, J=4.58, 1.53 Hz,1H). (ESI) m/z 318 (M+H)⁺.

EXAMPLE 404-{4-[(5-methoxy[1,3]thiazolo[5,4-b]pyridin-2-yl)methyl]-1-piperazinyl}phenolEXAMPLE 40A 2-(chloromethyl)-5-methoxy[1,3]thiazolo[5,4-b]pyridine

3-Amino-6-methoxy-2-pyridinethiol (0.8 g, Maybridge Co.) and2-chloro-1,1,1-triethoxyethane (1.26 g) were combined in ethanol (5 mL)and heated at 90° C. in a sealed tube for 2 hours. The mixture wasallowd to cool to room temperature and filtered. The filtrate wasconcentrated under reduced pressure and the residue was purified byflash chromatography (2:1, dichloromethane:hexanes) to provide the titlecompound. ¹H NMR (CDCl₃, 300 MHz) δ 4.00 (3H, s), 4.88 (2H, s), 6.88(1H, d, J=8.7 Hz), 8.10 (1H, d, J=8.7 Hz); MS (DCI/NH₃) m/z 215.0(M+H)⁺.

EXAMPLE 40B4-{4-[(5-methoxy[1,3]thiazolo[5,4-b]pyridin-2-yl)methyl]-1-piperazinyl}phenol

The product from Example 40A (0.184 mmol) and 4-(1-piperazinyl)phenol (3equivalents) were combined in acetonitrile (1 mL) and stirred at 25° C.for 24 hours. The mixture was evaporated to dryness and the residue wasrecrystallized from dimethylsulfoxide/methanol to provide the titlecompound. ¹H NMR (CD₃OD/CDCl₃, 300 MHz) δ 2.80 (4H, t, J=5.7 Hz), 3.12(4H, t, J=5.7 Hz), 3.98 (2H, s), 4.02 (3H, s), 6.78 (2H, d, J=8.7 Hz),6.81 (1H, d, J=8.7 Hz), 6.85 (2H, d, J=8.7 Hz), 8.04 (1H, d, J=8.7 Hz);MS (DCI/NH₃) m/z 357 (M+H)⁺.

EXAMPLE 412-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}-5-methoxy[1,3]thiazolo[5,4-b]pyridine

The product from Example 40A (0.184 mmol) and1-(2-fluorophenyl)piperazine (3 equivalents) were processed as describedin Example 40B to provide the title compound. ¹H NMR (CD₃OD/CDCl₃, 300MHz) δ 2.83 (4H, m), 3.08 (4H, m), 3.98 (2H, s), 4.01 (3H, 6.85 (1H, d,J=8.7 Hz), 6.95–7.09 (5H, m), 8.08 (1H, d, J=8.7 Hz). MS (DCI/NH₃) m/z359 (M+H)⁺.

EXAMPLE 425-methoxy-2-({4-[2-(methylthio)phenyl]-1-piperazinyl}methyl)[1,3]thiazolo[5,4-b]pyridine

The product from Example 40A (0.184 mmol) and1-[2-(methylthio)phenyl]piperazine (3 equivalents) were processed asdescribed in Example 40B to provide the title compound. ¹H NMR(CD₃OD/CDCl₃, 300 MHz) δ 2.41 (s, 3H), 2.85 (4H, m), 3.10 (4H, m), 4.00(2H, s), 4.05 (3H, s), 6.85 (1H, d, J=8.7 Hz), 7.15 (4H, m), 8.10 (1H,d, J=8.7 Hz); MS (DCI/NH₃) m/z 387 (M+H)⁺.

EXAMPLE 435-methoxy-2-{[4-(6-methyl-2-pyridinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine

The product from Example 40A (0.184 mmol) and1-(6-methyl-2-pyridinyl)piperazine (3 equivalents) were processed asdescribed in Example 40B to provide the title compound. ¹H NMR(CD₃OD/CDCl₃, 300 MHz) δ 2.55 (3H, s), 2.78 (4H, m), 3.60 (4H, m), 3.98(2H, s), 4.05 (3H, s), 6.48 (1H, d, J=8.7 Hz), 6.55 (1H, d, J=8.7 Hz),6.82 (1H, d, J=8.7 Hz), 7.40 (1H, m), 8.08 (1H, d, J=8.7 Hz); MS(DCI/NH₃) m/z 356 (M+H)⁺.

EXAMPLE 445-methoxy-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine

The product from Example 40A (0.184 mmol) and 1-(2-pyridinyl)piperazine(3 equivalents) were processed as described in Example 40B to providethe title compound. ¹H NMR (CD₃OD/CDCl₃, 300 MHz) δ 2.77 (4H, t, J=5.7Hz), 3.60 (4H, t, J=5.7 Hz), 3.96 (2H, s) 4.01 (3H, s), 6.65 (2H, m),6.82 (1H, d, J=8.71 Hz), 7.50 (1H, m), 8.04 (1H, d, J=8.7 Hz), 8.18 (1H,m); MS (DCI/NH₃) m/z 342 (M+H)⁺.

EXAMPLE 455-methoxy-2-{[4-(2-pyrimidinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine

The product from Example 40A (0.184 mmol) and2-(1-piperazinyl)pyrimidine (3 equivalents) were processed as describedin Example 40B to provide the title compound. ¹H NMR (CD₃OD/CDCl₃, 300MHz) δ 2.72 (4H, t, J=5.7 Hz), 3.85 (4H, t, J=5.7 Hz), 3.94 (2H, s),4.01 (3H, s), 6.50 (1H, t, J=5.4 Hz), 6.84 (1H, d, J=8.7 Hz), 8.04 (1H,d, J=8.7 Hz), 8.30 (2H, s); MS (DCI/NH₃) m/z 343 (M+H)⁺.

EXAMPLE 465-methoxy-2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine

The product from Example 40A (0.184 mmol) and1-(2-methoxyphenyl)piperazine (3 equivalents) were processed asdescribed in Example 40B to provide the title compound. ¹H NMR(CD₃PD/CDCl₃, 300 MHz) δ 2.84 (4H, m), 3.14 (4H, m), 3.88 (3H, s), 3.98(2H, s), 4.00 (3H, s), 6.84 (1H, d, J=8.7 Hz), 6.90–7.1 (4H, m), 8.06(1H, d, J=8.7 Hz); MS (DCI/NH₃) m/z 371 (M+H)⁺.

EXAMPLE 472-{[4-(2-chlorophenyl)-1-piperazinyl]methyl}-5-methoxy[1,3]thiazolo[5,4-b]pyridine

The product from Example 40A (0.184 mmol) and1-(2-chlorophenyl)piperazine (3 equivalents) were processed as describedin Example 40B to provide the title compound. ¹H NMR (CD₃OD/CDCl₃, 300MHz) δ 2.83 (4H, m), 3.18 (4H, m), 3.99 (2H, s), 4.01 (3H, s), 6.83 (1H,d, J=8.7 Hz), 6.99 (1H, m), 7.08 (1H, dd, J=7.5, 1.5 Hz), 7.22 (1H, m),7.36 (1H, d, J=7.5, 1.5 Hz), 8.03 (1H, d, J=8.7 Hz); MS (DCI/NH₃) m/z375 (M+H)⁺.

EXAMPLE 482-{4-[(5-methoxy[1,3]thiazolo[5,4-b]pyridin-2-ylmethyl]-1-piperazinyl}benzonitrile

The product from Example 40A (0.184 mmol) and2-(1-piperazinyl)benzonitrile (3 equivalents) were processed asdescribed in Example 40B to provide the title compound. ¹H NMR(CD₃OD/CDCl₃, 300 MHz) δ 2.90 (4H, m), 3.30 (4H, m), 4.01 (5H, s), 6.85(1H, d, J=8.7 Hz), 7.04 (2H, m), 7.50 (1H, m), 7.68 (1H, m), 8.08 (1H,d, J=8.7 Hz); MS (DCI/NH₃) m/z 366 (M+H)⁺.

EXAMPLE 495-methoxy-2-[(4-phenyl-1-piperazinyl)methyl][1,3]thiazolo[5,4-b]pyridine

The product from Example 40A (0.184 mmol) and 1-phenylpiperazine (3equivalents) were processed as described in Example 40B to provide thetitle compound. ¹H NMR (CD₃OD/CDCl₃, 300 MHz) δ 2.82 (4H, m), 3.25 (4H,m), 3.86 (2H, s), 4.02 (3H, s), 6.85 (1H, d, J=8.7 Hz), 6.95 (4H, m),7.25 (1H, m), 8.03 (1H, d, J=8.7 Hz); MS (DCI/NH₃) m/z 341 (M+H)⁺.

EXAMPLE 502-{[4-(2-chlorophenyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine

0.31 mmol), and DIEA (110 μL, 0.66 mmol) were processed as described inExample 38B to provide the title compound. ¹H NMR (500 MHz, DMSO-d₆) δ2.77 (m, 4H) 3.12 (m, 4H) 4.06 (s, 2H) 7.03 (m, 1H) 7.19 (m, 1H) 7.29(m, 1H) 7.39 (dd, J=7.96, 1.40 Hz, 1H) 7.54 (dd, J=8.11, 4.68 Hz, 1H)8.31 (dd, J=8.11, 1.56 Hz, 1H) 8.58 (dd, J=4.68, 1.56 Hz, 1H) (ESI) m/z345 (M+H)⁺.

EXAMPLE 512-{[4-(6-methyl-2-pyridinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine

The product from Example 38A (150 mg, 0.81 mmol),1-(6-methyl-2-pyridinyl)piperazine (160 mg, 0.98 mmol), and DIEA (280μL, 1.6 mmol) were processed as described in Example 38B to provide thetitle compound. ¹H NMR 1H NMR (300 MHz, DMSO-d₆) δ 2.68 (m, 4H) 3.32 (s,3H) 3.53 (m, 4H) 4.04 (s, 2H) 6.54 (m, 1H) 6.61 (d, J=8.48 Hz, 1H) 7.40(m, 1H) 7.56 (dd, J=8.31, 4.58 Hz, 1H) 8.33 (dd, J=8.31, 1.53 Hz, 1H);(ESI) m/z 326 (M+H)⁺.

EXAMPLE 522-{[4-(5-chloro-2-methoxyphenyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine

The product from Example 8A (150 mg, 0.81 mmol),1-(5-chloro-2-methoxyphenyl)piperazine (160 mg, 0.98 mmol), and DIEA(280 μL, 1.6 mmol) were processed as described in Example 38B to providethe title compound. ¹H NMR (300 MHz, DMSO-d₆) δ 2.74 (m, 4H) 3.05 (m,4H) 3.77 (s, 3H) 4.05 (s, 2H) 6.93 (m, 2H) 7.56 (dd, J=8.31, 4.58 Hz,2H) 8.33 (dd, J=8.14, 1.70 Hz, 1H) 8.59 (dd, J=4.58, 1.53 Hz, 1H); (ESI)m/z 375 (M+H)⁺.

EXAMPLE 534-[4-([1,3]thiazolo[5,4-b]pyridin-2-ylmethyl)-1-piperazinyl]phenol

The product from Example 38A (150 mg, 0.81 mmol),4-(1-piperazinyl)phenol (160 mg, 0.98 mmol), and DIEA (280 μL, 1.6 mmol)were processed as described in Example 38B to provide the titlecompound. ¹H NMR (300 MHz, DMSO-d₆) δ 2.73 (m, 4H) 3.02 (m, 4H) 4.03 (s,2H) 6.72 (m, 4H) 7.56 (dd, J=8.14, 4.75 Hz, 1H) 8.33 (dd, J=8.14, 1.70Hz, 1H) 8.59 (dd, J=4.58, 1.53 Hz, 1H): (ESI) m/z 327 (M+H)⁺.

EXAMPLE 542-[4-([1,3]thiazolo[5,4-b]pyridin-2-ylmethyl)-1-piperazinyl]nicotinonitrile

The product from Example 38A (150 mg, 0.81 mmol),2-(1-piperazinyl)nicotinonitrile (160 mg, 0.98 mmol), and DIEA (280 μL,1.6 mmol) were processed as described in Example 38B to provide thetitle compound. ¹H NMR (300 MHz, DMSO-d₆) δ 2.75 (m, 4H) 3.68 (m, 4H)4.07 (s, 2H) 6.94 (m, 1H) 7.56 (m, 1H) 8.08 (dd, J=7.80, 2.03 Hz, 1H)8.33 (dd, J=8.31, 1.53 Hz, 1H) 8.42 (dd, J=4.75, 1.70 Hz, 1H) 8.60 (dd,J=4.58, 1.53 Hz, 1H); (ESI) m/z 337 (M+H)⁺.

EXAMPLE 552-({4-[2-(methylthio)phenyl]-1-piperazinyl}methyl[1,3]thiazolo[5,4-b]pyridine

The product from Example 38A (150 mg, 0.81 mmol),1-[2-(methylthio)phenyl]piperazine (160 mg, 0.98 mmol), and DIEA (280μL, 1.6 mmol) were processed as described in Example 38B to provide thetitle compound. ¹H NMR (300 MHz, DMSO-d₆) δ 2.37 (s, 3H) 2.75 (m, 4H)2.97 (m, 4H) 4.06 (s, 2H) 7.13 (m, 3H) 7.56 (dd, J=8.31, 4.58 Hz, 2H)8.33 (dd, J=8.14, 1.36 Hz, 1H) 8.59 (dd, J=4.58, 1.53 Hz, 1H); (ESI) m/z357 (M+H)⁺.

EXAMPLE 562-{[4-(2-pyrimidinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine

The product from Example 38A (150 mg, 0.81 mmol),2-(1-piperazinyl)pyrimidine (160 mg, 0.98 mmol), and DIEA (280 μL, 1.6mmol were processed as described in Example 38B to provide the titlecompound. ¹H NMR (300 MHz, DMSO-d₆) δ 2.65 (m, 4H) 3.80 (m, 4H) 4.04 (s,2H) 6.63 (t, J=4.92 Hz, 1H) 7.56 (dd, J=8.14, 4.75 Hz, 1H) 8.34 (m, 2H)8.43 (d, J=4.75 Hz, 1H) 8.59 (dd, J=4.75, 1.70 Hz, 1H); (ESI) m/z 313(M+H)⁺.

EXAMPLE 572-{[4-(2-pyridinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine

The product from Example 38A (150 mg, 0.81 mmol),1-(2-pyridinyl)piperazine (160 mg, 0.98 mmol), and DIEA (280 μL, 1.6mmol) were processed as described in Example 38B to provide the titlecompound. ¹H NMR (300 MHz, DMSO-d₆) δ 2.80 (m, 4H) 3.55 (m, 4H) 4.04 (s,2H) 6.63 (m, 1H) 6.81 (m, 1H) 7.53 (m, 2H) 8.11 (m, 1H) 8.33 (dd,J=8.14, 1.70 Hz, 1H) 8.59 (dd, J=4.58, 1.53 Hz, 1H); (ESI) m/z 312(M+H)⁺.

EXAMPLE 582-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine

The product from Example 38A (200 mg, 1.1 mmol),1-(2-fluorophenyl)piperazine (215 mg, 1.2 mmol), and DIEA (380 μL, 2.2mmol) were processed as described in Example 38B to provide the titlecompound. ¹H NMR (300 MHz, DMSO-d₆) δ 2.77 (m, 4H) 3.10 (m, 4H) 4.06 (s,2H) 7.08 (m, 4H) 7.56 (dd, J=8.14, 4.75 Hz, 1H) 8.33 (dd, J=8.31, 1.53Hz, 1H) 8.59 (dd, J=4.58, 1.53 Hz, 1H); (ESI) m/z 329 (M+H)⁺.

EXAMPLE 592-[4-([1,3]thiazolo[5,4-b]pyridin-2-ylmethyl)-1-piperazinyl]benzonitrile

The product from Example 38A (680 mg, 3.7 mmol),2-(1-piperazinyl)benzonitrile (823 mg, 4.4 mmol), and DIEA (1.3 μL, 7.4mmol) were processed as described in Example 38B to provide the titlecompound. ¹H NMR (300 MHz, DMSO-d₆) δ 2.80 (m, 4H) 3.23 (m, 4H) 4.09 (s,2H) 7.13 (m, 1H) 7.21 (d, J=8.14 Hz, 1H) 7.59 (m, 2H) 7.71 (dd, J=7.80,1.70 Hz, 1H) 8.34 (dd, J=8.14, 1.70 Hz, 1H) 8.59 (dd, J=4.75, 1.70 Hz,1H); (ESI) m/z 336 (M+H)⁺.

EXAMPLE 602-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine

The product from Example 38A (200 mg, 1.1 mmol),1-(2-methoxyphenyl)piperazine (229 mg, 1.2 mmol), and DIEA (380 μL, 2.2mmol) were processed as described in Example 38B to provide the titlecompound. ¹H NMR (300 MHz, DMSO-d₆) δ 2.74 (m, 4H) 3.02 (m, 4H) 3.78 (s,3H) 4.04 (s, 2H) 6.91 (m, 3H) 7.56 (dd, J=8.31, 4.75 Hz, 2H) 8.33 (dd,J=8.14, 1.70 Hz, 1H) 8.59 (dd, J=4.75, 1.70 Hz, 1H); (ESI) m/z 341(M+H)⁺.

EXAMPLE 612-[(4-phenyl-1-piperazinyl)methyl][1,3]thiazolo[5,4-b]pyridine

The product from Example 38A (200 mg, 1.1 mmol), 1-phenylpiperazine (193mg, 1.2 mmol), and DIEA (380 μL, 2.2 mmol) were processed as describedin Example 38B to provide the title compound. ¹H NMR (300 MHz, DMSO-d₆)δ 2.74 (m, 4H) 3.19 (m, 4H) 4.05 (s, 2H) 6.78 (t, J=7.29 Hz, 1H) 6.95(d, J=7.80 Hz, 2H) 7.22 (m, 2H) 7.56 (dd, J=8.15, 4.75 Hz, 1H) 8.33 (dd,J=8.15, 1.70 Hz, 1H) (dd, J=4.75, 1.70 Hz, 1H); (ESI) m/z 311 (M+H)⁺.

EXAMPLE 622-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazoleEXAMPLE 62A 2-(chloromethyl)-1H-thieno[3,4-d]imidazole

3,4-Thiophenediamine (0.5 g, Toronto Research Chemicals, ChemicalAbstracts # 90069-81-1) and 2-chloro-1,1,1-triethoxyethane (0.9 g) werecombined in dimethoxyethane (7 mL) in a sealed tube and heated at 95° C.for one hour. After allowing to cool to room temperature and stirringfor 24 hours, the mixture was treated with hexane (10 mL) and filtered.The filter cake was dried under reduced pressure to provide the titlecompound. MS (DCI/NH₃) m/z 173 (M+H)⁺.

EXAMPLE 62B2-{[4-(2-fluorophenol)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole

The product from Example 62A (0.23 mmole) and1-(2-fluorophenyl)piperazine (1 mmole) were combined indimethylsulfoxide (1 mL) and stirred at 25° C. for 24 hours. The mixturewas partitioned between CH₂Cl₂ (4 mL), butanol (0.1 mL), and dilutedaqueous ammonia (15 mL). The organic phase was separated andconcentrated under reduced pressure. The residue was purified by flashchromatography on silica gel (19:1:0.1 CH₂Cl₂:methanol:ammoniumhydroxide) to provide the title compound. ¹H NMR (CD₃OD, 300 MHz) δ 2.8(4H, m), 3.18 (4H, m), 3.86 (2H, s), 6.9–7.1 (m, 6H); MS (DCI/NH₃) m/z317 (M+H)⁺.

EXAMPLE 632-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole

The product from Example 62A (0.23 mmol) and1-(2-methoxyphenyl)piperazine (1 mmole) were processed as described inExample 62B. ¹H NMR (CD₃OD, 300 MHz) δ 1.65 (m, 4H), 2.62 (2H, s), 2.90(4H, m), 3.85 (3H, s), 6.9 (m, 5H), 7.05 (m, 1H); MS (DCI/NH₃) m/z 329(M+H)⁺.

EXAMPLE 642-{[4-(2-pyrimidinyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole

The product from Example 62A (0.23 mmol) and 2-(1-piperazinyl)pyrimidine(1 mmol) were processed as described in Example 62B. ¹H NMR (CD₃OD, 300MHz) δ 2.75 (4H, m), 3.80 (2H, s), 3.90 (4H, m), 6.52 (t, 1H, J=5.4 Hz),6.80 (m, 2H), 8.31 (d, 2H, J=5.4 Hz). MS (DCI/NH₃) m/z 301 (M+H)⁺.

EXAMPLE 652-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole

The product from Example 62A (0.23 mmol) and 1-(2-pyridinyl)piperazine(1 mmol) were processed as described in Example 62B. ¹H NMR (CD₃OD, 300MHz) δ 2.63 (4H, t, J=5.7 Hz), 3.58 (4H, t, J=5.7 Hz), 3.75 (2H, s),6.65 (dd, 1H, J=7.5, 5.4 Hz), 6.82 (d, 1H, J=8.7 Hz), 6.85 (m, 2H), 7.57(1H, m), 8.08 (m, 1H); MS (DCI/NH₃) m/z 300 (M+H)⁺.

EXAMPLE 662-[4-(1H-thieno[3,4-d]imidazol-2-ylmethyl)-1-piperazinyl]nicotinonitrile

The product from Example 62A (0.23 mmol) and2-(1-piperazinyl)nicotinonitrile (1 mmol) were processed as described inExample 62B. ¹H NMR (CD₃OD, 300 MHz) δ 2.79 (4H, m), 3.82 (6H, m), 6.90(m, 2H), 8.34 (dd, 1H, J=7.8, 4.8 Hz), 7.80 (dd, 1H, J=7.8, 1.5 Hz),8.34 (dd, 1H, J=4.8, 1.5 Hz); MS (DCI/NH₃) m/z 325 (M+H)⁺.

EXAMPLE 674-[4-(1H-thieno[3,4-d]imidazol-2-ylmethyl)-1-piperazinyl]phenol

The product from Example 62A (0.23 mmol) and 4-(1-piperazinyl)phenol (1mmol) were processed as described in Example 62B. ¹H NMR (CD₃OD, 300MHz) δ 2.78 (4H, t, J=5.4 Hz), 3.11 (4H, t, J=5.4 Hz), 3.79 (2H, s),6.76 (2H, J=8.7 Hz), 6.90 (m, 4H), 7.8 (s, 1H); MS (DCI/NH₃) m/z 315(M+H)⁺.

EXAMPLE 682-({4-[2-(methylthio)phenyl]-1-piperazinyl}methyl)-1H-thieno[3,4-d]imidazole

The product from Example 62A (0.23 mmol) and1-[2-(methylthio)phenyl]piperazine (1 mmol) were processed as describedin Example 62B. ¹H NMR (CD₃OD, 300 MHz) δ 1.65 (m, 4H), 2.40 (3H, s),3.0 (6H, m), 7.1 (6H, m); MS (DCI/NH₃) m/z 345 (M+H)⁺.

EXAMPLE 69–84

The synthesis of the chemical intermediate1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxide has been describedin Cui, Donghui; Davis, Margaret R.; Dunn, Michael; Evans, Ben E.; Kari,Hanumath P.; Lagu, Bharat; Nagarathnam, Dhanapalan; Vyas, Kamlesh P.;Zhang, Kanyin. Preparation ofdifluorophenyldihydro-pyrimidinecarboxamides as α1a receptorantagonists. U.S. (2001), 27 pp. U.S. Pat. No. 6,274,585 B1. It can alsobe prepared by the following route:

To a solution of diisopropylamine (13.4 mL. 96 mmol) in THF (350 mL) at−78° C. was added 1.6M nBuLi in hexane (60 mL, 96 mmol). The reactionmixture was stirred for 5 min at −78° C. A solution oft-butoxycarbonyl-4-piperidone (16 g, 80 mmol) in THF (100 mL) was addedand the reaction mixture was stirred for 10 min. Then a solution ofN-phenyltrifluoromethanesulfonimide (31.4 g, 88 mmol) was added. Thereaction mixture was stirred at −78° C. for 30 min and the cooling bathwas removed to warm it up to room temperature (˜1.5 hr). The reactionwas quenched by saturated NaHCO₃ followed by extraction with ethyl etherand 5% citric acid. The organic layer was then washed with 1NaOH (4×200mL), and water (2×200 mL), and by saturated aqueous NaCl (1×200 mL),dried over MgSO₄, and evaporated on rotary evaporator to give yellowishoil. Purification by flash chromatography using Hexane:Ethyl acetate 8:2as eluent gave 18 g of4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acidtert-butyl ester as a pure colorless oil. ¹H NMR (300 MHz, DMSO-d₆) δ1.41 (s, 9H), 2.41 (m, 2H), 3.54 (t, 2H), 3.98 (m, 2H), 6.02 (m, 1H).

Next, a pure solution of4-trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acidtert-butyl ester (18 g, 54 mmol) in THF (˜200 mL) was treated with2-pyridylzinc bromide 0.5 molar solution in THF (from Aldrich, browncolor) (124 mL, 62.5 mmol, 1.15 eq.) followed by Pd(PPh₃)₄ (from StremChemicals) (625 mg). The reaction mixture was heated at 60° C. for 90minutes. The THF was removed by rotary evaporator. Ethyl acetate (300mL) and 1 N NaOH (200 mL) were added to the residue, and the zinc saltswere removed by filtration. The organic layer was separated and washedwith brine (300 mL), dried (MgSO4), and concentrated on the rotaryevaporator to give brown oil. Purification by flash chromatography usingHexane:Ethyl acetate 6:4 as eluent gave 9.0 g (64% yield) of3′,6′-dihydro-2′H-[2,4′]bipyridinyl-1′-carboxylic acid tert-butyl esteras colorless oil. ¹H NMR (300 MHz, DMSO-d₆) δ 1.43 (s, 9H), 2.56 (m,2H), 3.54 (t, 2H), 4.04 (m, 2H), 6.08 (m, 1H), 7.25 (dd, 1H), 7.56 (d,J=9 Hz, 1H), 7.77 (m, 1H), 8.54 (m, 1H); MS (DCI—NH₃) m/z 259 (M+H)⁺,277 (M+H+18)⁺

Next, 3′,6′-Dihydro-2′H-[2,4′]bipyridinyl-1′-carboxylic acid tert-butylester (9.0 g) was hydrogenated using 10% Pd/C dry (900 mg) at 60 psi atroom temperature for 1.5 hr to give 8.9 g (99%) of3′,4′,5′,6′-tetrahydro-2′H-[2,4′]bipyridinyl-1′-carboxylic acidtert-butyl ester as a colorless oil. ¹H NMR (300 MHz, DMSO-d₆) δ 1.41(s, 9H), 1.58 (m, 2H), 1.81 (m, 2H), 2.85 (m, 3H), 4.06 (m, 2H), 7.20(dd, 1H), 7.28 (d, J=9 Hz, 1H), 7.70 (m, 1H), 8.48 (m, 1H).

Next, 3′,4′,5′,6′-tetrahydro-2′H-[2,4′]bipyridinyl-1′-carboxylic acidtert-butyl ester (8.9 g, 33.9 mmol) in dichloromethane (30 mL) wascooled to 0° C. and treated with m-chloroperbenzoic acid 77% (10.5 g,61.06 mmol, 1.8 eq.). The reaction mixture was stirred at 0° C. for 30minutes then at room temperature for 2 hours, CH₂Cl₂ (50 mL) was addedto the reaction mixture and washed with saturated NaHCO₃ then withbrine, dried over MgSO₄, concentrated in vacuo. The residue wastriturated with 5% CH₂Cl₂ in hexane to give1-oxy-3′,4′,5′,6′-tetrahydro-2′H-[2,4′]bipyridinyl-1′-carboxylic acidtert-butyl ester as a white solid, ¹H NMR (300 MHz, DMSO-d₆) δ 1.41 (s,9H), 1.42 (m, 2H), 1.90 (m, 2H), 2.83 (m, 2H), 3.45 (m, 1H), 4.09 (m,2H), 7.30 (m, 2H), 7.40 (m, 1H), 8.26 (m, 1H).

Next, 3′,4′,5′,6′-tetrahydro-2′H-[2,4′]bipyridinyl-1′-carboxylic acidtert-butyl ester (6.57 g) was dissolved in ethyl acetate (150 mL) andcooled to −78° C. HCl gas was bubbled through the reaction mixture for15 min. The reaction mixture was allowed to warm up to room temperatureupon which a precipitate was formed. The precipitate was filtered andwashed with ethyl acetate, dried under high vacuum to give the HCl saltof the desired product1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxide (5.04 g, 99%yield). ¹H NMR (300 MHz, DMSO-d₆) δ 1.82 (m, 2H), 2.10 (m, 2H), 3.06 (m,2H), 3.36 (m, 2H), 3.58 (m, 1H), 7.45 (m, 3H), 8.39 (d, J=9 Hz, 1H),9.04 (bs, 1H); MS (DCI—NH₃) m/z 179 (M+H)⁺, 163 (M+H−16)⁺.

The preparation of the chemical intermediate1-(1-oxy-pyridin-2-yl)-piperazine has been described in Regnier, et al.Arzneim. Forsch. (1974) 24, p 1964–1970; and as it's hydrochloride saltin Taveras, Arthur G.; Aki, Cynthia J.; Bond, Richard W.; Chao,Jianping; Dwyer, Michael; Ferreira, Johan A.; Chao, Jianhua; Yu,Younong; Baldwin, John J.; Kaiser, Bernd; Li, Ge; Merritt, J. Robert;Nelson, Kingsley H.; Rokosz, Laura L. Preparation of 3,4-di-substitutedcyclobutene-1,2-diones as cxc-chemokine receptor ligands. PCT Int. Appl.(2002), 394 pp. WO 0283624 A1.

By the method used to prepare1-[(5-chloro-1-benzothien-3-yl)methyl]-4-(6-methyl-2-pyridinyl)piperazine,3-(Bromomethyl)-5-chloro-1-benzothiophene may be reacted with1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxide to prepare1′-(5-Chloro-benzo[b]thiophen-3-ylmethyl)-1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxide.

By the method used to prepare1-[(5-chloro-1-benzothien-3-yl)methyl]-4-(6-methyl-2-pyridinyl)piperazine,3-(Bromomethyl)-5-chloro-1-benzothiophene may be reacted with1-(1-oxy-pyridin-2-yl)-piperazine to prepare1-(5-Chloro-benzo[b]thiophen-3-ylmethyl)-4-(1-oxy-pyridin-2-yl)-piperazine.

By the method used to prepare2-[4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1-piperazinyl]benzonitrile,1H-pyrrolo[2,3-b]pyridine may be reacted with formaldehyde and1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxide to prepare1′-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxide.

By the method used to prepare2-[4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1-piperazinyl]benzonitrile,1H-pyrrolo[2,3-b]pyridine may be reacted with formaldehyde and1-(1-oxy-pyridin-2-yl)-piperazine to prepare3-[4-(1-Oxy-pyridin-2-yl)-piperazin-1-ylmethyl]-1H-pyrrolo[2,3-b]pyridine.

By the method used to prepare4-(4-{[6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]methyl}-1-piperazinyl)phenol,[6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]methyl methanesulfonatemay be reacted with 1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxideto prepare1′-(6-Trifluoromethyl-thieno[3,2-b]pyridin-2-ylmethyl)-1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxide.

By the method used to prepare4-(4-{[6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]methyl}-1-piperazinyl)phenol,[6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]methyl methanesulfonatemay be reacted with2-[4-(1-Oxy-pyridin-2-yl)-piperazin-1-ylmethyl]-6-trifluoromethyl-thieno[3,2-b]pyridine.

By the method used to prepare2-[(4-phenyl-1-piperazinyl)methyl]furo[3,2-b]pyridine,furo[3,2-b]pyridine-2-carbaldehyde may be reacted with1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxide to prepare1′-Furo[3,2-b]pyridin-2-ylmethyl-1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxide.

By the method used to prepare2-[(4-phenyl-1-piperazinyl)methyl]furo[3,2-b]pyridine,furo[3,2-b]pyridine-2-carbaldehyde may be reacted with1-(1-oxy-pyridin-2-yl)-piperazine to prepare2-[4-(1-Oxy-pyridin-2-yl)-piperazin-1-ylmethyl]-furo[3,2-b]pyridine.

By the method used to prepare2-{[4-(2-pyridinyl)-1-piperidinyl]methyl}[1,3]thiazolo[5,4-b]pyridine,2-(chloromethyl)[1,3]thiazolo[5,4-b]pyridine may be reacted with1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxide to prepare1′-Thiazolo[5,4-b]pyridin-2-ylmethyl-1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxide.

By the method used to prepare2-{[4-(2-pyridinyl)-1-piperidinyl]methyl}[1,3]thiazolo[5,4-b]pyridine,2-(chloromethyl)[1,3]thiazolo[5,4-b]pyridine may be reacted with1-(1-oxy-pyridin-2-yl)-piperazine to prepare2-[4-(1-Oxy-pyridin-2-yl)-piperazin-1-ylmethyl]-thiazolo[5,4-b]pyridine.

By the method used to prepare4-{4-[(5-methoxy[1,3]thiazolo[5,4-b]pyridin-2-yl)methyl]-1-piperazinyl}phenol,2-(chloromethyl)-5-methoxy[1,3]thiazolo[5,4-b]pyridine was reacted with1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxide to prepare1′-(5-Methoxy-thiazolo[5,4-b]pyridin-2-ylmethyl)-1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxide.

5-Methoxy-2-[4-(1-oxy-pyridin-2-yl)-piperazin-1-ylmethyl]-thiazolo[5,4-b]pyridine

By the method used to prepare4-{4-[(5-methoxy[1,3]thiazolo[5,4-b]pyridin-2-yl)methyl]-1-piperazinyl}phenol,2-(chloromethyl)-5-methoxy[1,3]thiazolo[5,4-b]pyridine was reacted with1-(1-oxy-pyridin-2-yl)-piperazine to prepare5-Methoxy-2-[4-(1-oxy-pyridin-2-yl)-piperazin-1-ylmethyl]-thiazolo[5,4-b]pyridine.

By the process used to prepare2-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole,2-(chloromethyl)-1H-thieno[3,4-d]imidazole was reacted with1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxide to prepare1′-(1H-Thieno[3,4-d]imidazol-2-ylmethyl)-1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl1-oxide

By the process used to prepare2-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole,2-(chloromethyl)-1H-thieno[3,4-d]imidazole was reacted with1-(1-oxy-pyridin-2-yl)-piperazine2-[4-(1-Oxy-pyridin-2-yl)-piperazin-1-ylmethyl]-1H-thieno[3,4-d]imidazole.

In Vitro Data Functional Activity of D₄

Efficacies and potencies of compounds of the present invention at thehuman D₄ receptor were determined using a stable cell line containingthe human D_(4.4) receptor and a chimeric G protein in HEK-293 cells.This cell line allows a robust calcium signal detectable using a calciumfluorescent dye and a fluorescent imaging plate reader (FLIPR) (Cowardet al., Anal. Biochem. 270: 242–248, 1999). Cells were plated(20000/well) into 96 well dishes and cultured for 48 hours. Media isremoved, Fluo-4 dye added and cells incubated 1 hour at roomtemperature. Cells are washed with phosphate buffered saline to removeexcess dye and compounds to be tested added to the wells and signalmeasured in FLIPR. Percent efficacy is the maximum response produced bythe compound in relation to the maximum effect of 10 μM dopamine. TheEC₅₀ is the effective concentration of the compound that causes 50% ofthe compound's maximum response.

Chimeric G-proteins allow a high-throughput signaling assay ofGi-coupled receptors, P. Coward, S. Chan, H. Wada, G. Humpries and B.Conklin, Analytical Biochemistry 270, 242–248 (1999).

Representative compounds of the present invention exhibited EC_(50s) inthe range of 7.5 nM to 3800 nM.

In Vivo Data Rat Penile Erection Model

Wistar rats were used as a primary animal model to study penile erectionin vivo. All experiments were carried out between 9:00 AM and 3:00 PM ina diffusely illuminated testing room with a red light. Animals wereweighed and allowed to adapt to the testing room for 60 minutes beforethe beginning of experiments. Rats were placed individually in atransparent cage (20×30×30 cm) after drug injection. The number ofpenile erections were recorded by direct observation for a period of 60minutes after drug dosing, and the number of animals exhibiting 1 ormore erections was expressed as incidence (%). (L)-Ascorbic acid insaline (1 mg/mL) was used as vehicle and apomorphine was used as apositive control at a dose of 0.1 μmol/kg.

Representative compounds of the present invention induced a minimum of30% incidence of penile erections in rats after subcutaneousadministration at doses of 0.01 μmol/kg to 1.0 μmol/kg.

The in vitro and in vivo data demonstrates that compounds of the presentinvention are dopamine D₄ receptor agonists that induce penile erectionsin rats.

As dopamine D₄ receptor agonists, compounds of the present invention canbe used in combination with phosphodiesterase 5 inhibitors including,but not limited to, sildenafil or vardenafil as a method of treatingsexual dysfunction in a mammal.

As dopamine D₄ receptor agonists, compounds of the present invention canbe used in combination with an adrenergic receptor antagonist including,but not limited to, terazosin, prazosin or tamsulosin as method oftreating sexual dysfunction in a mammal.

As dopamine D₄ receptor agonists, compounds of the present invention canbe used in combination with a dopamine agonist including, but notlimited to, apomorphine as a method of treating sexual dysfunction in amammal.

Compounds of the present invention are dopamine D₄ receptor agonists andtherefore are useful for the treatment of male sexual dysfunction,female sexual dysfunction, attention deficit hyperactivity disorder,Alzheimer's disease, drug abuse, Parkinson's disease, anxiety,schizophrenia, mood disorders and depression, as described in: Thedopamine D₄ receptor: a controversial therapeutic target, N. J. Hrib,Drugs of the future 25:587–611 (2000); Dopamine and sexual behavior, M.Melis and A. Argiolas, Neuroscience and Biobehavioral Reviews 19:19–38(1995); and Dopamine receptors: from structure to function, C. Missale,S. R. Nash, S. Robinson, M. Jabber and M. Caron, Physiological Reviews78: 189–225 (1998).

Compounds of the present invention are dopamine D₄ receptor agonists andtherefore are useful for the treatment of cardiovascular disorders.Dopamine and dopaminergic agents have been reported to exertpharmacologically significant cardiovascular effects on blood pressureand heart rate and are useful in the treatment of cardiovasculardisorders, as described in: Chen F F, and Lin M T, Effects of dopamine,apomorphine gamma-hydroxybutyric acid, haloperidol, and pimozide onreflex bradycardia in rats, Journal of Pharmacology and ExperimentalTherapeutics (1980) 214: 427–432; and it has been reported that primatedata support the potential clinical utility of dopamine receptoragonists in treating cardiovascular disease, as described in: Hahn, R Aand MacDonald B R, Primate cardiovascular responses meditated bydopaminine receptors: effects of N,N-dipropyldopamine and LY171555,Journal of Phamacology and Experimental Therapeutics (1984) 229:132–138.

Compounds of the present invention are dopamine D₄ receptor agonists andtherefore are useful for the treatment of inflammation. Dopaminergicagents can exert anti-inflammatory effects and are useful for thetreatment of diseases where inflammation plays a deleterious role, asdescribed in: Bendele A M, Spaethe S M, Benslay D N, and Bryant H U,Anti-inflammatory activity of pergolide, a dopamine receptor agonist, inJournal of Pharmacology of Pharmacology and Experimental Therapeutics(1991) 259 169–175. Dopaminergic agents can also be of utility in thetreatment of cancers, as described in: Lissoni P, Mandala M, Giani L,Malugani F, Secondino S, Zonato S, Rocco F, Gardani G, Efficacy ofBromocriptine in the Treatment of Metastatic Breast Cancer and ProstateCancer-related Hyperprolactinemia, Neuroendocrinology Letters (2000) 21405–408.

The term agonist, as used herein, means a compound of the presentinvention that exhibits 30% or greater efficacy in the in vitro assaydescribed herein.

The term “pharmaceutically acceptable carrier” as used herein, means anon-toxic, inert solid, semi-solid or liquid filler, diluent,encapsulating material or formulation auxiliary of any type. Someexamples of materials which can serve as pharmaceutically acceptablecarriers are sugars such as lactose, glucose and sucrose; starches suchas corn starch and potato starch; cellulose and its derivatives such assodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate;powdered tragacanth; malt; gelatin; talc; such as cocoa butter andsuppository waxes; oils such as peanut oil, cottonseed oil, saffloweroil, sesame oil, olive oil, corn oil and soybean oil; glycols; such apropylene glycol; esters such as ethyl oleate and ethyl laurate; agar;buffering agents such as magnesium hydroxide and aluminum hydroxide;alginic acid; pyrogen-free water; isotonic saline; Ringer's solution;ethyl alcohol, and phosphate buffer solutions, as well as othernon-toxic compatible lubricants such as sodium lauryl sulfate andmagnesium stearate, as well as coloring agents, releasing agents,coating agents, sweetening, flavoring and perfuming agents,preservatives and antioxidants can also be present in the composition,according to the judgment of the formulator. The present inventionprovides pharmaceutical compositions which comprise compounds of thepresent invention formulated together with one or more non-toxicpharmaceutically acceptable carriers. The pharmaceutical compositionscan be formulated for oral administration in solid or liquid form, forparenteral injection or for rectal administration.

Dosage forms for topical administration of a compound of the presentinvention include powders, sprays, ointments and inhalants. The activecompound is mixed under sterile conditions with a pharmaceuticallyacceptable carrier and any needed preservatives, buffers or propellantswhich can be required. Opthalmic formulations, eye ointments, powdersand solutions are also contemplated as being within the scope of thisinvention.

Actual dosage levels of active ingredients in the pharmaceuticalcompositions of this invention can be varied so as to obtain an amountof the active compound(s) which is effective to achieve the desiredtherapeutic response for a particular patient, compositions, and mode ofadministration. The selected dosage level will depend upon the activityof the particular compound, the route of administration, the severity ofthe condition being treated, and the condition and prior medical historyof the patient being treated.

When used in the above or other treatments, a therapeutically effectiveamount of one of the compounds of the present invention can be employedin pure form or, where such forms exist, in pharmaceutically acceptablesalt, ester, amide, or prodrug form. Alternatively, the compound can beadministered as a pharmaceutical composition containing the compound ofinterest in combination with one or more pharmaceutically acceptablecarriers. The phrase “therapeutically effective amount” of the compoundof the present invention means a sufficient amount of the compound totreat disorders, at a reasonable benefit/risk ratio applicable to anymedical treatment. The specific therapeutically effective dose level forany particular patient will depend upon a variety of factors includingthe disorder being treated and the severity of the disorder; activity ofthe specific compound employed; the specific composition employed; theage, body weight, general health, sex and diet of the patient; the timeof administration, route of administration, and rate of excretion of thespecific compound employed; the duration of the treatment; drugs used incombination or coincidental with the specific compound employed; andlike factors well known in the medical arts.

The total daily dose of the compounds of the present inventionadministered to a mammal, and particularly a human, may range from about0.001 to about 30 mg/kg/day. For purposes of oral administration, morepreferable doses can be in the range of from 0.01 to about 10 mg/kg/day.If desired, the effective daily dose can be divided into multiple dosesfor purposes of administration; consequently, single dose compositionsmay contain such amounts or submultiples thereof to make up the dailydose.

The present invention also provides pharmaceutical compositions thatcomprise compounds of the present invention formulated together with oneor more non-toxic pharmaceutically acceptable carriers. Thepharmaceutical compositions can be specially formulated for oraladministration in solid or liquid form, for parenteral injection or forrectal administration.

The pharmaceutical compositions of this invention can be administered tohumans and other mammals orally, rectally, parenterally,intracisternally, intravaginally, intraperitoneally, topically (as bypowders, ointments or drops), bucally or as an oral or nasal spray. Theterm “parenterally” as used herein, refers to modes of administrationwhich include intravenous, intramuscular, intraperitoneal, intrasternal,subcutaneous and intraarticular injection and infusion.

Pharmaceutical compositions of this invention for parenteral injectioncomprise pharmaceutically acceptable sterile aqueous or nonaqueoussolutions, dispersions, suspensions or emulsions as well as sterilepowders for reconstitution into sterile injectable solutions ordispersions just prior to use. Examples of suitable aqueous andnonaqueous carriers, diluents, solvents or vehicles include water,ethanol, polyols (such as glycerol, propylene glycol, polyethyleneglycol and the like), vegetable oils (such as olive oil), injectableorganic esters (such as ethyl oleate) and suitable mixtures thereof.Proper fluidity can be maintained, for example, by the use of coatingmaterials such as lecithin, by the maintenance of the required particlesize in the case of dispersions and by the use of surfactants.

These compositions may also contain adjuvants such as preservatives,wetting agents, emulsifying agents and dispersing agents. Prevention ofthe action of microorganisms can be ensured by the inclusion of variousantibacterial and antifungal agents, for example, paraben,chlorobutanol, phenol sorbic acid and the like. It may also be desirableto include isotonic agents such as sugars, sodium chloride and the like.Prolonged absorption of the injectable pharmaceutical form can bebrought about by the inclusion of agents which delay absorption such asaluminum monostearate and gelatin.

In some cases, in order to prolong the effect of the drug, it isdesirable to slow the absorption of the drug from subcutaneous orintramuscular injection. This can be accomplished by the use of a liquidsuspension of crystalline or amorphous material with poor watersolubility. The rate of absorption of the drug then depends upon itsrate of dissolution which, in turn, may depend upon crystal size andcrystalline form. Alternatively, delayed absorption of a parenterallyadministered drug form is accomplished by dissolving or suspending thedrug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices ofthe drug in biodegradable polymers such as polylactide-polyglycolide.Depending upon the ratio of drug to polymer and the nature of theparticular polymer employed, the rate of drug release can be controlled.Examples of other biodegradable polymers include poly(orthoesters) andpoly(anhydrides). Depot injectable formulations are also prepared byentrapping the drug in liposomes or microemulsions which are compatiblewith body tissues.

The injectable formulations can be sterilized, for example, byfiltration through a bacterial-retaining filter or by incorporatingsterilizing agents in the form of sterile solid compositions which canbe dissolved or dispersed in sterile water or other sterile injectablemedium just prior to use.

Solid dosage forms for oral administration include capsules, tablets,pills, powders and granules. In such solid dosage forms, the activecompound may be mixed with at least one inert, pharmaceuticallyacceptable carrier, such as sodium citrate or dicalcium phosphate and/ora) fillers or extenders such as starches, lactose, sucrose, glucose,mannitol and silicic acid; b) binders such as carboxymethylcellulose,alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; c)humectants such as glycerol; d) disintegrating agents such as agar-agar,calcium carbonate, potato or tapioca starch, alginic acid, certainsilicates and sodium carbonate; e) solution retarding agents such asparaffin; f) absorption accelerators such as quaternary ammoniumcompounds; g) wetting agents such as cetyl alcohol and glycerolmonostearate; h) absorbents such as kaolin and bentonite clay and i)lubricants such as talc, calcium stearate, magnesium stearate, solidpolyethylene glycols, sodium lauryl sulfate and mixtures thereof. In thecase of capsules, tablets and pills, the dosage form may also comprisebuffering agents.

Solid compositions of a similar type may also be employed as fillers insoft and hard-filled gelatin capsules using lactose or milk sugar aswell as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills and granulescan be prepared with coatings and shells such as enteric coatings andother coatings well-known in the pharmaceutical formulating art. Theymay optionally contain opacifying agents and may also be of acomposition such that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract, optionally,in a delayed manner. Examples of embedding compositions which can beused include polymeric substances and waxes.

Liquid dosage forms for oral administration include pharmaceuticallyacceptable emulsions, solutions, suspensions, syrups and elixirs. Inaddition to the active compounds, the liquid dosage forms may containinert diluents commonly used in the art such as, for example, water orother solvents, solubilizing agents and emulsifiers such as ethylalcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzylalcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol,dimethyl formamide, oils (in particular, cottonseed, groundnut, corn,germ, olive, castor and sesame oils), glycerol, tetrahydrofurfurylalcohol, polyethylene glycols and fatty acid esters of sorbitan andmixtures thereof.

Besides inert diluents, the oral compositions may also include adjuvantssuch as wetting agents, emulsifying and suspending agents, sweetening,flavoring and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspendingagents as, for example, ethoxylated isostearyl alcohols, polyoxyethylenesorbitol and sorbitan esters, microcrystalline cellulose, aluminummetahydroxide, bentonite, agar-agar, tragacanth and mixtures thereof.

Compositions for rectal or vaginal administration are preferablysuppositories which can be prepared by mixing the compounds of thepresent invention with suitable non-irritating carriers such as cocoabutter, polyethylene glycol or a suppository wax which are solid at roomtemperature but liquid at body temperature and therefore melt in therectum or vaginal cavity and release the active compound.

Compounds of the present invention can also be administered in the formof liposomes. As is known in the art, liposomes are generally derivedfrom phospholipids or other lipid substances. Liposomes are formed bymono- or multi-lamellar hydrated liquid crystals which are dispersed inan aqueous medium. Any non-toxic, physiologically acceptable andmetabolizable lipid capable of forming liposomes can be used. Thepresent compositions in liposome form can contain, in addition to acompound of the present invention, stabilizers, preservatives, and thelike. The preferred lipids are natural and synthetic phospholipids andphosphatidyl cholines (lecithins) used separately or together.

Methods to form liposomes are known in the art. See, for example,Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, NewYork, N.Y. (1976), p. 33 et seq.

The present invention contemplates pharmaceutically active compoundseither chemically synthesized or formed by in vivo biotransformation tocompounds of formula (I).

The compounds of the invention can exist in unsolvated as well assolvated forms, including hydrated forms, such as hemi-hydrates. Ingeneral, the solvated forms, with pharmaceutically acceptable solventssuch as water and ethanol among others are equivalent to the unsolvatedforms for the purposes of the invention.

The term “pharmaceutically acceptable salt, ester, amide, and prodrug”as used herein, refers to carboxylate salts, amino acid addition salts,zwitterions, esters, amides, and prodrugs of compounds of formula (I)which are within the scope of sound medical judgement, suitable for usein contact with the tissues of humans and lower animals without unduetoxicity, irritation, allergic response, and the like, are commensuratewith a reasonable benefit/risk ratio, and are effective for theirintended use.

The compounds of the present invention can be used in the form ofpharmaceutically acceptable salts derived from inorganic or organicacids. The term “pharmaceutically acceptable salt” means those saltswhich are, within the scope of sound medical judgement, suitable for usein contact with the tissues of humans and lower animals without unduetoxicity, irritation, allergic response and the like and arecommensurate with a reasonable benefit/risk ratio. Pharmaceuticallyacceptable salts are well-known in the art. The salts can be prepared insitu during the final isolation and purification of the compounds of thepresent invention or separately by reacting a free base function with asuitable organic acid. Representative acid addition salts include, butare not limited to acetate, adipate, alginate, citrate, aspartate,benzoate, benzenesulfonate, bisulfate, butyrate, camphorate,camphorsufonate, digluconate, glycerophosphate, hemisulfate, heptanoate,hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide,2-hydroxyethansulfonate(isethionate), lactate, maleate,methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate,pectinate, persulfate, 3-phenylpropionate, picrate, pivalate,propionate, succinate, sulfate, bis(tartrate), tartrate, (L)tartrate,bis((L)tartrate), (D)tartrate, bis((L)tartrate), (DL)tartrate,bis((DL)tartrate), meso-tartrate, bis(meso tartrate), thiocyanate,phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate.Examples of acids which can be employed to form pharmaceuticallyacceptable acid addition salts include such inorganic acids ashydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acidand such organic acids as maleic acid, fumaric acid, succinic acid andcitric acid.

Basic addition salts can be prepared in situ during the final isolationand purification of compounds of this invention by reacting a carboxylicacid-containing moiety with a suitable base such as the hydroxide,carbonate or bicarbonate of a pharmaceutically acceptable metal cationor with ammonia or an organic primary, secondary or tertiary amine.Pharmaceutically acceptable salts include, but are not limited to,cations based on alkali metals or alkaline earth metals such as lithium,sodium, potassium, calcium, magnesium and aluminum salts and the likeand nontoxic quaternary ammonia and amine cations including ammonium,tetramethylammonium, tetraethylammonium, methylamine, dimethylamine,trimethylamine, triethylamine, diethylamine, ethylamine and the like.Other representative organic amines useful for the formation of baseaddition salts include ethylenediamine, ethanolamine, diethanolamine,piperidine, piperazine and the like. Preferred salts of the compounds ofthe present invention include phosphate, tris and acetate.

The term “pharmaceutically acceptable prodrug” or “prodrug” as usedherein, represents those prodrugs of the compounds of the presentinvention which are, within the scope of sound medical judgement,suitable for use in contact with the tissues of humans and lower animalswithout undue toxicity, irritation, allergic response, and the like,commensurate with a reasonable benefit/risk ratio, and effective fortheir intended use. Prodrugs of the present invention may be rapidlytransformed in vivo to compounds of formula (I), for example, byhydrolysis in blood.

The term “pharmaceutically acceptable ester” or “ester” as used herein,refers to esters of compounds of the present invention which hydrolyzein vivo and include those that break down readily in the human body toleave the parent compound or a salt thereof. Examples ofpharmaceutically acceptable, non-toxic esters of the present inventioninclude C₁-to-C₆ alkyl esters and C₅-to-C₇ cycloalkyl esters, althoughC₁-to-C₄ alkyl esters are preferred. Esters of the compounds of formula(I) may be prepared according to conventional methods.

The term “pharmaceutically acceptable amide” or “amide” as used herein,refers to non-toxic amides of the present invention derived fromammonia, primary C₁-to-C₆ alkyl amines and secondary C₁-to-C₆ dialkylamines. In the case of secondary amines, the amine may also be in theform of a 5- or 6-membered heterocycle containing one nitrogen atom.Amides derived from ammonia, C₁-to-C₃ alkyl primary amides and C₁-to-C₂dialkyl secondary amides are preferred. Amides of the compounds offormula (I) may be prepared according to conventional methods.

1. A compound of formula (II)

or a pharmaceutically acceptable salt, or N-oxide, thereof, wherein A isselected from the group consisting

V is selected from the group consisting of CR_(V) and N; R_(V), isindependently selected from the group consisting of hydrogen, alkoxy,alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl,alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl,halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro,—NZ₁Z₂, (NZ₃Z₄)carbonyl, and (NZ₃Z₄)sulfonyl; R_(Y) is selected from thegroup consisting of hydrogen, alkenyl, alkoxycarbonyl, alkyl, arylalkyl,and (NZ₃Z₄)carbonyl; Z₁ and Z₂ are each independently selected from thegroup consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl,arylalkyl, arylalkylsulfonyl, arylsulfonyl, and formyl; Z₃ and Z₄ areeach independently selected from the group consisting of hydrogen,alkyl, aryl, and arylalkyl; L is alkylene; D is selected from the groupconsisting of

 wherein the left end is attached to L and the right end is attached toB₁; R_(A) is selected from the group consisting of hydrogen and alkyl; Zis N; --- is absent; B₁ is selected from the group consisting of

R₁, R₂, R₃, R₄ and R₅ are each independently selected from the groupconsisting of hydrogen, alkoxy, alkenyl, alkyl, alkylsulfinyl,alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl,alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy,haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, —NZ₁Z₂,(NZ₃Z₄)carbonyl, and (NZ₃Z₄)sulfonyl; X₁ is selected from the groupconsisting of N(R₆), O and S; Y₁ is selected from the group consistingof C(R₇) and N; R₆ is selected from the group consisting of hydrogen andalkyl; and R₇ is selected from the group consisting of hydrogen andalkyl.
 2. The compound according to claim 1 wherein


3. The compound according to claim 1 wherein

R_(Y) is selected from the group consisting of hydrogen and alkyl; andR₁, R₂, R₃, and R₄ are independently selected from the group consistingof hydrogen, alkoxy, alkyl, alkylthio, cyano, and halogen.
 4. Thecompound according to claim 3 selected from the group consisting of2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole; and2-[4-(1H-thieno[3,4-d]imidazol-2-ylmethyl)-1-piperazinyl]nicotinonitrile.5. The compound according to claim 1 wherein


6. The compound according to claim 5 wherein R_(Y) is selected from thegroup consisting of hydrogen and alkyl; and R₁, R₂, R₃, R₄, and R₅ areindependently selected from the group consisting of hydrogen, alkoxy,alkyl, alkylthio, cyano, halogen, and hydroxy.
 7. The compound accordingto claim 6 selected from the group consisting of2-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole;2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole;4-[4-(1H-thieno[3,4-d]imidazol-2-ylmethyl)-1-piperazinyl]phenol; and2-({4-[2-(methylthio)phenyl]-1-piperazinyl}methyl)-1H-thieno[3,4-d]imidazole.8. The compound according to claim 1 wherein


9. The compound according to claim 8 wherein R_(Y) is selected from thegroup consisting of hydrogen and alkyl; and R₂, R₃, and R₄ areindependently selected from the group consisting of hydrogen, alkyl, andhalogen.
 10. The compound according to claim 9 that is2-{[4-(2-pyrimidinyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole.